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Vaccines have long been delivered with a hypodermic needle and syringe. Several 
drawbacks of this method include patient pain, biohazardous sharps waste, and the need 
for administration by a healthcare worker. Aside from the delivery method, vaccines are 
also relatively unstable outside of a controlled cold-chain of refrigeration and freezer 
equipment. Most current vaccines are stored either refrigerated at 2-8°C or frozen at -20°C 
throughout storage and transportation, adding substantial cost to immunization programs 
from both the maintenance of a controlled cold-chain as well as vaccine wastage when that 
cold-chain fails. A novel drug delivery method currently being developed, called a 
microneedle patch, could possibly mitigate all of these disadvantages. 
Microneedle patches are composed of submillimeter projections, called 
microneedles (MNs), arranged in an array on a solid backing. These MNs are composed of 
water soluble excipients and polymers with the drug encapsulated inside the MN. When 
the MNs are inserted into skin, they dissolve in the interstitial fluid and release their 
payload. The backing is then removed from the skin, and the procedure is complete. There 
is no sharps waste generated with this painless delivery, and it may be possible for patients 
to self-administer their patches. Also, MN patches exist in a dried state, possibly lending 
itself to the stability of any vaccine inside of it. 
The first aim of this work was to screen possible MN formulations to maintain 
influenza vaccine antibody-binding activity during air drying on flat surfaces 
representative of the production process and during subsequent storage without 
refrigeration. Initial work began from established coated MN formulations developed 
previously with 15% w/v trehalose and 1% w/v carboxymethylcellulose. Vaccine was 
buffer exchanged into various buffer solutions and dried at three different temperatures. In 
general, drying quickly at 40°C caused slightly more vaccine activity loss compared to 
drying at 4°C or 25°C. To simplify later testing, 25°C was chosen as the drying temperature 
because it was not detrimental to stability. Phosphate-buffered saline, while suitable for 
many aqueous proteins, led to a significant loss of activity after drying for a short time. 
Two buffers, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) and 
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ammonium acetate, both performed well, and ammonium acetate was chosen as the buffer 
for all subsequent formulation studies. Surfactants, while helpful for creating a coated MN, 
were not found to have an effect on vaccine activity during initial drying, and were thus 
omitted from further formulations. A large number of compounds were screened for 
stability, with the majority of good performing stabilizers being carbohydrates, with the 
noted exceptions of arginine and histidine. Previous evidence from work with dry measles 
formulation suggested a combination of stabilizers could be beneficial, so combinations of 
top stabilizers were tested for up to one month at 40°C. Three formulations were found to 
have no statistically significant loss of activity throughout the month of storage as well as 
no activity loss at 40°C for up to eighteen months. These formulations were 50/50 
combinations of trehalose/sucrose, sucrose/arginine, and arginine/heptagluconate. They 
were then implemented into the production of influenza vaccine microneedle patches. 
Both monovalent and trivalent influenza vaccine microneedles were produced with 
the three top stabilizer combinations. These patches were shown to be stable for up to 
eighteen months at 25°C, which is more prolonged than would need be for annual seasonal 
influenza vaccine patches. A set of patches with the stabilizer combination of 
arginine/heptagluconate that had shown full stability after 12 months was used to vaccinate 
BALB/c mice. Compared to comparable doses of vaccine delivered intradermally with a 
needle and syringe, both aged and fresh patches elicited a higher antibody response. To 
remove the effect of delivery method, some aged patches were reconstituted in buffer and 
delivered intradermally as well. These showed comparable antibody titers to the same dose 
of fresh vaccine delivered intradermally. As added measures of vaccine stability in 
microneedle patches, patches formulated with arginine and heptagluconate were subjected 
to freeze-thaw cycles, 60°C storage for four months, and electron beam irradiation. None 
of these conditions caused a statistically significant loss of vaccine activity. 
For a deeper look into influenza vaccine stability during drying, the mechanism of 
activity loss was investigated with a number of protein analytical techniques. Dynamic 
light scattering (DLS) and transmission electron microscopy both showed multimeric 
rosettes typical of subunit vaccines as well as larger spherical protein structures. While the 
size and frequency of these larger structures were not noticeably different between liquid 
and dried vaccine when analyzed by transmission electron microscopy (TEM), DLS did 
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show a more chaotic size distribution for dried vaccine. This phenomenon was prevented 
by the inclusion of trehalose in the vaccine solution before drying. Protein structure 
changes were also probed with spectroscopic techniques. Circular dichroism spectroscopy 
and intrinsic protein fluorescence spectroscopy essentially showed no structural changes, 
and the few changes that were found, while statistically significant, were not deemed to be 
the cause of vaccine activity loss. Therefore the predominant mechanism of influenza 
vaccine activity loss was aggregation. 
Overall, this work sought to develop a dissolving MN patch that can preserve 
subunit influenza vaccine in vitro activity and in vivo immunogenicity. MN patches 
developed here have been shown to be both robust against several potentially harsh 
conditions and maintained vaccine activity throughout long-term storage outside of the 
cold-chain. These same aged patches generated seropositive antibody titers in mice. 
Finally, it was determined that the primary mechanism of vaccine activity loss during 
drying is aggregation. We foresee MN patches help to increase vaccination coverage 
through higher patient compliance and a cheaper, more immunogenic, and more stable 







The introduction of vaccines has seen a dramatic drop in many diseases that once 
caused widespread human death and suffering. They teach the body to fight infections 
before the disease causing agent can cause too much harm. The most widespread method 
to deliver these vaccines is a hypodermic needle and a syringe. Vaccine delivery to the skin 
via microneedles confers several advantages over the traditional hypodermic needle and 
syringe. This work focuses on developing microneedles as a thermostable delivery method 
for the influenza vaccine that can be completely removed from the cold-chain, thus 
minimizing cost and wastage during storage and transportation. This removal from the cold 
chain will allow for cheaper and more wide-spread vaccination campaigns. The 
development and commercialization of microneedle patches could improve overall 
vaccination coverage in both developed and developing countries, eliminated much of the 






2.1 Influenza virus and vaccine 
The disease known as the flu is caused by the influenza virus, an RNA virus of the 
Orthomyxoviridae family.[1] These typically spherical or filamentous virus particles 
consist of 8 strains of RNA, which encode a total of 11 proteins.[2] Two of these proteins 
are hemagglutinin and neuraminidase, both of which are surface membrane proteins that 
are believed to be the basis of human immunological responses.[3] Hemagglutinin (HA) is 
a glycoprotein responsible for attachment to the host cell as well as membrane fusion with 
the host cell to facilitate introduction of viral cargo.[4] Neuraminidase (NA) is also a 
glycoprotein which facilitates the release of newly formed virus particles by cleaving the 
sialic acid sites of the cell membrane.[5] 
The 3 different genera of influenza are known as influenza virus A, influenza virus 
B, and influenza virus C.[5] Although humans can be infected by influenza C, usually 
during early childhood, it is much rarer than infection by influenza A or B.[6] Current 
vaccines consist of two strains of influenza A and one or two strains of influenza B.[7] The 
primary antigen that the influenza vaccine is based on is HA.[8] Typical seasonal influenza 
vaccines contain roughly 15 µg of HA from each of the three strains predicted by the World 
Health Organization to best match the circulating strains for a given year.[9] The strains 
chosen include two influenza A strains and one influenza B strain, although a quadrivalent 
influenza vaccine which contains a second influenza B strain has been approved in the 
United States.[10] 
HA is a 225 kDa homotrimer glycoprotein formed from three 75 kDa monomers, 
each of which is composed of two subunits, HA1 and HA2 (Figure 2.1).[5] The specific 
amino acid sequence of HA is dependent on the strain of influenza, but the overall structure 
is relatively unchanged across strains.[11] HA is synthesized within the host cell as a non-
fusogenic precursor, HA0, before being glycosylated and cleaved to create the fusogenic 
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form, where HA1 and HA2 are connected by a disulfide bond.[12] The overall structure of 
HA is an elongated coiled-coil stalk with a large globular head.[13] HA’s roles in infection 
are performed by the two subunits on each monomer. The large globular head, derived 
from HA1, is responsible for binding to sialic acid on the target membrane.[14] The central 
triple-stranded coiled-coil stalk, derived from HA2, is responsible for fusion between the 
host membrane and viral membrane, thus creating a pore through which the viral payload 
can infect the target cell.[15] This fusion region, though, is not typically accessible before 
HA undergoes a low-pH induced conformational change after sialic acid binding and 
endocytosis.[16] This conformational change involves the globular head moving to the side 
of the protein while the central stock undergoes a refolding that exposes the membrane 
fusion region.[17] This conformational change has also been known to be caused by heat 
or urea treatment.[18] 
 
 
Figure 2.1. A cartoon representation of the ectodomain of influenza hemagglutinin. 
The strain depicted is from the B/Brisbane/60/2008 with each color representing a 






Current influenza vaccines generally are administered as one of 5 types of antigen 
particles: whole inactivated vaccine (WIV), live attenuated influenza vaccine (LAIV), 
virosomal vaccine, split virus vaccine, and subunit vaccine.[20] The first three types 
include an intact virus membrane. A whole inactivated vaccine is a virus particle that has 
been treated with formaldehyde[21] or β-propiolactone[22] such that the RNA is not able 
to be replicated inside the host cell.[22] The live attenuated vaccine is whole virus particles 
that have been cold-adapted by repeated passage through chicken eggs at decreasing 
temperatures.[23] The virus particles can then only survive in the nasal cavity and not in 
any internal organs.[24] Thus it elicits a mucosal immune response without a systemic 
infection.[23] The virosomal vaccine, such as Influvac® and Inflexal®, from Abbott 
Laboratories and Crucell Vaccines Inc., respectively, is also an intact membrane vesicle 
similar to WIV and LAIV. Instead of a modified whole virus, though, it is reconstituted 
from subunit particles, such as partial influenza envelopes, so that the interior of the 
membrane is void of genetic material.[25] Both split virus vaccines and subunit vaccines 
are manufactured by breaking whole virus particles into many smaller pieces such as RNA, 
intracellular proteins, and pieces of membrane with attached membrane proteins. However, 
a subunit vaccine has been purified to only contain pieces of membrane with attached 
membrane proteins.[26] This is due to the belief that the HA and NA proteins are what 
elicit human immune responses.[20] Owing to the aggregation of their hydrophobic 




Figure 2.2. Representative cartoons of various influenza vaccine types: (A) whole-




2.2 Current methods of vaccine delivery 
There are several routes of influenza vaccination currently being utilized. The most 
common method is an intramuscular (IM) injection using a syringe and a hypodermic 
needle. An aqueous suspension of vaccine, possibly along with any preservatives and 
adjuvants, are injected directly into muscle tissue. An adjuvant is a compound which helps 
boost the body’s immunological response to an antigen.[28] Possible modes of action of 
an adjuvant are immunomodulation, antigen presentation, cytotoxic T-lymphocyte 
induction, antigen presenting cell targeting, or depot formation.[29] Another similar 
method is subcutaneous (SC) injections. SC injections deposit the vaccine suspension 
directly in the fatty tissue directly beneath the dermal layer.[30] Intradermal (ID) injections 
delivery vaccine within the dermis layer of the skin.[31] This can be advantageous because 
of the higher density of antigen presenting cells, such as dermal dendritic cells and 
Langerhans cells.[32] 
Although a hypodermic needle and syringe is the most common form of vaccine 
delivery, there are drawbacks to all three major hypodermic injections. It is required that 
healthcare personnel administer the vaccine, and even with the training healthcare 
personnel receive, needle-stick injuries sometimes occur.[33] These can lead to the 
exposure to unknown pathogens and the transmission of blood-borne infectious 
diseases.[34] Since ID injections need to be more precise than IM or SC injections, even 
more training and skills are required for the person administering the dose.[35] 
Any route of vaccination using a needle and syringe has similar drawbacks. As 
stated, needle-stick injuries can introduce other pathogens to personnel, which can lead to 
transmission of infectious diseases.[36] Patients can be hesitant to receive any treatment 
via an injection due to the pain of injection and needle-phobia. This decreases patient 
compliance.[37]  Disposing of used needles presents a hazard because they must be 
disposed of safely as sharps biohazard waste. 
There are other, more novel routes of influenza vaccine. FluMist is an FDA-
approved intranasal delivery suspension/device. Currently being manufactured and 
marketed by MedImmune[38], it painlessly delivers an aerosolized LAIV mist directly to 
the nasal cavity to elicit an immune response.  
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Delivery methods are also being developed for intradermal[35, 39, 40] and 
transdermal[41, 42] routes. As of the 2011-2012 influenza season, an ID influenza vaccine 
has been approved and available in the United States.[43] Fluzone Intradermal, by Sanofi 
Pasteur, is available to adults 18 to 64 years of age and is delivered through a needle much 
smaller than a typical hypodermic needle.[43] The needle used is 1.5 mm in length, which 
is 90% shorter than other needles used for IM influenza vaccine delivery, and is used to 
deliver a 0.1 mL dose of trivalent vaccine.[44] It was found in a Phase III trial that a reduced 
dose delivered intradermally using a microinjection system provided comparable 
hemagglutination inhibition levels as the standard trivalent vaccine delivered 
intramuscularly.[45] Also approved for use in the United States, PharmaJet® Inc. utilizes 
a needleless jet injector to delivery bioCSL Inc.’s AFLURIA inactivated influenza vaccine 
into the skin.[46] The jet injector system allows for vaccine delivery without the generation 
of biohazardous sharps waste, but has been found to have a higher incidence rate of 
infection.[47] 
2.3 Microneedle basics 
A new method is being developed for delivery of vaccines into skin. This method 
uses solid projections called microneedles (MN). Each MN is less than 1 millimeter in 
length, and they are most often placed together with other MNs to form what is called a 
“patch”. The MNs are designed to be long enough so that they pass through the tough outer 
layer of the epidermis, called the stratum corneum, but short enough so that they do not 
contact the skin’s blood vessels or nerves. This can lead to an improved immune response 
compared to an IM injection[40, 48] with the nearly painless insertion of a MN patch[49]. 
The improved immune response is thought to be a result of a large population of immune 
cells in the skin, such as Langerhans cells and dermal dendritic cells.[50, 51] It has been 
shown that MN vaccinations, when compared to IM vaccinations, induce cellular and 
humoral immune responses that by some measures are significantly greater.[52] 
There are several different varieties of MN patches (Figure 2.3). The simplest one 
is essentially a shorter version of a standard needle. These hollow MNs have a small-
diameter bore with a sharp tip and are designed to be long enough to pass just through the 
stratum corneum and into the epidermis and dermis.[53] A small volume of drug solution 
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can then be injected into the skin for either bolus or extended delivery.[54] The other type 
of MN that does not have any active pharmaceutical ingredient (API) incorporated directly 
with the design is the solid MN patch. These MNs, containing no API, are composed of 
solid metal[55, 56], polymer[57], or silicon[58] projections designed to insert through skin 
to disrupt the stratum corneum. After the MNs are fully inserted, they are removed to leave 
pores in the skin. Gels, creams, or passive transdermal patches are then placed on the skin 
over the pores so that the (API), which wouldn’t normally be able to diffuse well into the 
skin, can be delivered below the stratum corneum. This method is typically referred to as 
“poke and patch” delivery. 
 
 
Figure 2.3. Four different types of microneedle patches. (A) Microneedle patches 
upon initial insertion into skin. (B) Drug being delivered across the stratum corneum 
into the dermis and epidermis. Used with permission.[59] 
 
Another variety is the coated MN patch. Here a metal projection, made of 
metal[60, 61] or silicon[62, 63], is either cut out of a thin, flat sheet with laser ablation or 
chemical etching. After electropolishing and cleaning, the metal MNs are ready to be 
coated with the API to be delivered. This is done by repeated dip-coating into a solution 
of the API and any other formulation compounds that constitute the coating solution.[64] 
For many applications, a surfactant is necessary to help wet the entire hydrophobic metal 
surface.[65] A viscosity enhancer is also added to the solution to help form a thicker 
coating, thus allowing more API to be coated on the surface of the MNs.[66] The process 
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of dip-coating lends itself to automation by controlling the movement of either the 
coating solution reservoir or the MN arrays.[60] Once the MN patch has been coated, it 
can then be inserted into the skin where the needles penetrate into the epidermis. Once 
there, the coating dissolves and releases the API payload that it contains to be acted upon 
by the skin’s rich immune system environment.[67] 
 
 
Figure 2.4. Flowchart of the dissolving microneedle patch production process. 
 
The last type of MN covered here is the dissolving MN patch. Each MN is a solid 
projection comprised primarily of water-soluble polymers and stabilizing excipients.[68] 
As described by Vassilieva et.al.[69], the production method (Figure 2.4) used here is a 
liquid casting into polydimethylsiloxane (PDMS) molds with the assistance of vacuum. A 
solution of the API and other excipients, such as stabilizers and polymers, is placed on top 
of a negative PDMS mold with MN shaped cavities. The mold is the exposed to vacuum to 
help the solution completely fill the mold, removing a small pocket of air that can occur 
at the MN tip. Once the mold is filled, the API solution is allowed to dry down into the tips 
of the MN cavities. The final casting step is to fill the mold with a backing solution, which 
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will create the rest of each MN as well as a backing to facilitate the demolding of all the 
MNs together. In this work, this solution contains polyvinyl alcohol and sucrose, both of 
which are readily soluble in the skin’s interstitial fluid. With all of the components in place, 
the patch is then dried still in the mold with desiccant at room temperature for several 
days. The MN patch is then demolded and is ready to be used. The process of using a 
dissolving MN patch is very similar to that of a coated MN patch, except after MN 
insertion, the entire MN structure dissolves instead of simply a coating. This dissolution 
releases the API payload as well as ensures there is no sharps waste once the 
immunization is complete and the MN patch backing is removed from the skin.[70] 
2.4 Dry protein stabilization 
Viruses and vaccine-related proteins, like most biological structures, are 
accustomed to being inside a living system and, therefore, prefer to be in an aqueous 
environment.[71] During the manufacturing of MN patches, though, the environment that 
the vaccine is in becomes decreasingly aqueous to the point where can be considered dry 
and no longer aqueous. This change in surroundings can stress the vaccine, possibly to the 
extent that it is no longer active as the desired antigen.[72] Vaccine antibody-binding 
activity loss could occur during two different time frames with respect to MN patches. The 
first is the initial drying while the vaccine is being incorporated into the microneedle patch. 
The second is during the storage of these patches. Under certain conditions, such as high 
temperature or humidity, it is possible for the matrix compounds to change their physical 
state from one of a transient amorphous state to a more thermodynamically stable 
crystalline state. Thus, a production method and formulation must be developed to help 
maintain vaccine antigenicity and overall stability during the production and subsequent 
dry storage of MN patches. 
As the protein of interest in this work is an antigen for immunization, stabilization 
here refers to the ability of the protein to bind to antibodies in in vitro assays or to cause 
the production of antibodies in vivo. This ability to activate the immune system and induce 
the production of neutralizing antibodies determines whether the protein is still 
immunogenic. This definition of protein stability leaves open the possibility that small 
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changes, such as oxidation or deamidation, can occur to the protein without affecting its 
immunogenicity. 
One common criterion monitored for protein stability is protein aggregation, which 
is the interaction and association of multiple proteins.[73] Although aggregation is usually 
thought of as the association of hydrophobic regions of a protein, there are several 
pathways that can lead to protein aggregation.[74] Proteins typically have hydrophilic 
amino acid residues on their outer surfaces with more hydrophobic resides located in the 
core of the structure, away from their aqueous surrounding.[75] If circumstances occur that 
the hydrophobic core of a protein is exposed to its aqueous environment, due to events such 
as misfolding or structural rearrangement, it will then seek to find a more suitable 
interaction, whether this is a more hydrophobic interface or an exposed region of another 
protein.[76] Proteins may also self-associate by either electrostatic forces or through 
hydrophobic interactions without the involvement of an unfolded intermediate although 
they may involve subtle conformational changes.[74] 
The previously mentioned aggregation pathways do not involve chemical changes 
to the protein’s molecular composition. It is possible, though, for proteins to interact after 
a chemical change. One route is the direct chemical linkage of proteins. While the most 
common reaction is the breakage and reformation of disulfide bonds[77], it can also include 
reactions such as dityrosine formation[78], Maillard-type reactions[79], and formaldehyde-
mediated cross-linking[80]. Another route for protein aggregation to occur, is by chemical 
modification of amino acid residue side chains that changes the protein’s hydrophobicity, 
secondary or tertiary structure, or barriers to unfolding. These reactions include common 
protein modifications such as deamidation, oxidation, deglycosylation, or hydrolysis.[81] 
All of these chemical modifications could also occur without subsequent aggregation. 
These would be of interest with regards to vaccine stability if they were to occur in an 
antigenic region of the protein, thus causing a decrease of immunogenicity. 
Changes to the protein stability in an aqueous state can easily become exacerbated 
when the protein undergoes freezing or drying. In either case, the amount of liquid water 
proteins and excipients have available to interact with decreases drastically. This increases 
the concentration of all components in the remaining solution.[82] Several things can result 
from this concentration. Since aggregation is the interaction or association of multiple 
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proteins, an increase in protein concentration will hasten this process. The pH of a buffer 
can also be affected by the concentration of excipients in the protein formulation.[83] An 
example is phosphate-buffered saline, where the concentration of buffer components leads 
to a drop in solution pH due to differential precipitation of the buffer components since 
they all have different solubility limits.[84] This pH change affects protein stability as 
much as it would in a typical protein solution, although the extent of its effect is also 
dependent on the rate of freezing or drying. Rapid processing may limit the time that the 
protein has for changes to occur.[85] 
Many lessons for protein stabilization during drying can be found in the extensive 
work done for protein lyophilization. During the lyophilization process, protein solutions 
are frozen, placed in a low pressure chamber, and slowly warmed so that the frozen water 
sublimates directly to water vapor. This results in a product with a very low moisture 
content. These proteins are often formulated with certain excipients that have been found 
to help maintain protein stability in the dried state. 
These stabilizers are often carbohydrates. There are two theories, which could act 
together, of how a carbohydrate stabilizes biomolecules, such as proteins[86], 
liposomes[87], and viruses[88].  One theory involves the vitrification of sugar to form a 
sugar glass. This sugar glass is an amorphous phase characterized by extremely high 
viscosity.[89] Biomolecules in this phase are isolated[90] and restrained[91] so that 
aggregation and interactions are held to a minimum. The other theory is called the water-
displacement theory. Biomolecules form many hydrogen bonds with surrounding water 
molecules. Sugars, which contain hydroxyl groups, can replace these missing hydrogen 
bonds as water is removed. This helps maintain the environment necessary for the native 
structure of the biomolecule.[92] Preservation of the amorphous, glassy state is influenced 
by both storage temperature and overall matrix composition, which is affected by moisture 
content.[93] The thermodynamic stability of a glass is related to the difference between its 
storage temperature and its glass transition temperature, known as Tg.[94] This is a well-
studied point at which a material transitions from an amorphous, highly viscous glass phase 
to a higher mobility rubber phase.[95] If an amorphous solid is kept well below its Tg, then 
it will tend to remain in that state, but if its temperature approaches or surpasses its Tg, then 
it will transition into a rubbery state.[96] This point is described by the Gordon-Taylor 
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equation[97], which takes into account the composition of the material as well as the 
individual Tg of each component. Pure water has a Tg of -137°C[98], therefore small 
amounts of water in the solid phase lowers the Tg of the solid as a whole. For this reason, 
the hygroscopicity and ambient humidity of lyophilized products are closely monitored. 
Sugars which are commonly used as lyoprotectants, such as sucrose and trehalose, have 
relatively high Tg of 75-115°C[99] and 77°C[100], respectively, although the value 
depends on the measurement methodology. Thus these sugars help to maintain an 
amorphous, sugar glass matrix surrounding a biopharmaceutical drug. 
While trehalose and sucrose have been used widely in lyophilized 
biopharmaceutical products, other compounds have been studied and used as stabilizing 
excipients. Other disaccharides have also been investigated, such as maltose[101] and 
lactose[102], as well as monosaccharides and larger polysaccharides. A common 
stabilizing monosaccharide is glucose[103-105], while there are many polysaccharides 
such as dextran[106, 107] and inulin[108, 109]. The studies involving carbohydrates 
typically reference the compounds’ abilities to hydrogen bond with a protein or to form a 
glassy phase to immobilize and stabilize a protein. A factor to be aware of when selecting 
a carbohydrate to include in a formulation is that reducing sugars can lead to protein 
degradation during storage by Maillard reactions between their free carbonyls and the free 
amino groups on the protein.[110, 111] 
Not all stabilizing compounds must be saccharides, though. Salts can have a large 
impact on protein stability as well. Salt selection and concentration affect the presence or 
absence of a hydration shell around a given protein, thus determining whether the protein 
is “salted out” or “salted in”.[112-114] Zhang and Cremer reviewed the order in which 
salts and osmolytes have salting in or salting out properties, known as the Hofmeister 
series.[115] Although the exact mechanism of action of salts on proteins in solutions is not 
well defined, in general, ions that salt out proteins, such as sulfate and carbonate, prevent 
protein unfolding, thus stabilizing the protein.[116] It should be noted, though, that all 
formulation components are concentrated as a solution is frozen or dried, and salts can have 
different effects on proteins depending on their concentration ranges, thus care must be 
taken when simply choosing a salt at either end of the Hofmeister series. 
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Non-carbohydrate polymers have also been used to stabilize proteins in solution 
and in a dried state. The enzyme urokinase has been stabilized by hydroxyl ethyl starch, 
PEG4000, and gelatin.[117] Polyethylimine was used to stabilize the enzyme lactate 
dehydrogenase during storage.[118] A common characteristic of protein-stabilizing 
polymers is their hydrophilic nature.[119] Similar to saccharides’ favorable interaction 
through hydrogen bonding, hydrophilic polymers are able to satisfy electrostatic 
interactions[120] with the protein surface as well as forming an entangled matrix 
environment if present in the a dried formulation since many polymers have relatively high 
glass transition temperature, Tg.[121] 
Formulation development for proteins is still relatively empirical. There are several 
broadly successful excipients and general trends, but the development of a successful 
formulation is still prepared on a case-by-case basis. There are even more special 
considerations when working on stabilizing a vaccine formulation because there are many 
varieties of vaccine. Some vaccines are composed of only proteins, therefore formulation 
development can utilize the wide range of knowledge about stabilizing proteins. Other 
vaccines are intact viral particles. Inactivated vaccines must remain intact to retain full 
immunogenicity, and live attenuated vaccines must remain intact and alive so that they can 
replicate inside the patient. Altered osmolarity[122] and interfacial surface 
interactions[123] have been shown to negatively affect vaccine activity in the liquid and 
dried states. 
There are currently no DNA vaccines approved for human use in the United States, 
although they are in development. DNA vaccine development includes its own set of 
stability concerns such as DNA rearrangements [124] and nuclease degradation[125], for 
example. Polysaccharides are also utilized as vaccine components as bacterial capsular 
polysaccharide antigens.[126] Lone polysaccharides, while more stable than other 
biomacromolecules, are not strong antigens and therefore are conjugated to carrier proteins 
to increase antigenicity.[127] Polysaccharide conjugate vaccine stability can be lost by 
hydrolysis of the carbohydrate chains, proteolysis, and unfolding of the carrier 
protein.[128] 
Commercial influenza vaccine in the United States is always presented in a single 
or multidose vial filled with liquid formulation as well as prefilled syringes. Current 
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influenza vaccines have a listed shelf-life of one year[20], although this is the commercial 
shelf life; the true shelf-life is likely longer. Typical commercial subunit influenza subunit 
and live attenuated vaccines have been shown to lose essentially all of their potency after 
6 weeks and 2 weeks, respectively, when stored at 37°C.[129, 130] 
To increase this shelf-life, many groups are working on developing methods to 
lyophilize influenza vaccine. Examples excipients included in lyophilized or spray-dried 
formulations include trehalose[131-135], sucrose, inulin[108, 131, 136], dextran[131-133], 
and xylose[137]. These work by previously discussed mechanisms of glassy state 
formation and water replacement interactions. The most successful of these examples 
demonstrated influenza vaccine stability for up to 12 months at 4°C[133], 6 months at 
25°C[133], and 4 months at 40°C.[132] Influenza vaccine MN patches utilize similar 
stabilization schemes[122, 138-140] as well as methylcellulose[141]. Hirobe et.al. also 
employed sodium hyaluranate to create dissolving MN patches that remained stable for up 
to six months at 40°C.[142] 
2.5 Vaccine characterization techniques 
There are a variety of methods to characterize vaccines. Depending on the specific 
interest, it can be as straightforward as using a vaccine to immunize an animal model to 
reveal changes in antibody titers or as detailed as a biochemical assessment of protein 
changes down to the single amino acid residue. The level of investigation is dependent on 
the stage of vaccine development and the level of detail necessary for the questions being 
asked.  
Arguably the most important technique used to characterize a vaccine is an activity 
assay. For a human vaccine, human test subjects would be the most ideal model to test the 
efficacy and activity of a given vaccine, but there are obvious disadvantages of testing 
vaccines of a significant level of uncertainty on people. Therefore the next step down is to 
test a vaccine on a suitable animal model. The animal species chosen for testing must be 
able to respond to vaccination in a way that is correlative to a human’s response. This is 
either having an immune system capable of responding to a specific type of vaccine or 
having the ability to mimic a human disease.[143] A suitable model for influenza in the 
murine model.[144] After immunization, the mice produce strain-specific anti-HA 
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antibodies which can be collected in serum. Antibody titers in serum can be measured by 
a hemagglutination inhibition assay, as described by the World Health Organization[145], 
where serum and live virus are incubated together to allow the antibodies to neutralize the 
viral particles. These neutralized viral particles are then no longer capable of agglomerating 
added erythrocytes. The amount of erythrocyte agglomeration correlates to the titer of anti-
HA antibodies, thus the overall response of each mouse to the immunization. 
When an animal model is either not available or too expensive, the next alternative 
is an in vitro activity assay. For live, attenuated vaccines, it is common for cell infectivity 
to be a marker of vaccine activity. Measles vaccine study utilizes an endpoint tissue 
infectivity assay to determine the titer of live viral particles that are needed to kill a certain 
percentage of a cell culture.[146] Samples of live measles vaccine is applied to a monolayer 
of cells and the active vaccine titer is determined by the percentage of cells killed by 
measles virus.[146] Development of rubella vaccine involves an immunocolorimetric 
assay, described by Chen et.al.[147], where a sample of vaccine is applied to a monolayer 
of cells and allowed to infect these cells, if possible. An antibody specific to a rubella 
surface protein is then added to bind to rubella particles, allowing for the quantification of 
live rubella particles in the initial sample. 
When there are no live viral particles to measure infectivity, other in vitro methods 
must be used. A common method for measuring the activity of vaccines based around 
proteins, whether subunit, recombinant, or conjugate, is an enzyme-linked immunosorbent 
assay, known as an ELISA, as described by Gan and Patel.[148] ELISAs are based on the 
principle of antibody-antigen binding. There are three different types of ELISA: direct, 
sandwich, and competitive. In a direct ELISA, a sample containing an antigen of interest, 
usually a protein, is allowed to bind to a microwell plate. Subsequently, antigen-specific 
antibody, which is conjugated to an enzyme such as horseradish peroxidase, is added to 
each well. The conjugated enzyme causes a change in an added substrate such that the 
change in the substrate is back-correlated with the amount of enzyme, thus the amount of 
antigen in each well. Other examples of vaccine activity assays. Sandwich ELISAs are very 
similar to direct ELISAs except that the antigen of interest is not adhered to the well 
surface, but rather it is bound to an antibody which is adhered to the well surface. This 
allows for more control over antigen immobilization. The final type of ELISA discussed 
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here is the competitive ELISA. The key feature here is the competition to bind with 
antibodies between antigen incubated with antibody and antigen attached to the well 
surface; higher sample antigen concentration leads to less antibody to bind to surface 
antigens, thus a lower readout signal. 
If the stability of a subunit vaccine is to be studied at a deeper level, there are other, 
more detailed assays. Many vaccines are suitably sized to be examined by dynamic light 
scattering (DLS).[149] Whole viral particles can break apart[150] or aggregate[151] which 
leads to activity loss. This change in particle size distribution should be discernable from 
DLS measurements of the vaccine sample. Even in the case of influenza subunit vaccine, 
the HA membrane proteins associate together to form a multimeric rosette which is suitably 
large for examination by DLS.[152] In addition to using DLS to find the particle size 
distribution, structural details may be found by transmission electron microscopy.[27] This 
can help to determine whether there are well-ordered structures or more random 
aggregation. 
Influenza vaccine, based on the antigenicity of HA, is dependent on the structural 
integrity of the HA protein.[153] One method to monitor general changes to protein 
structure is intrinsic fluorescence spectroscopy. This intrinsic fluorescence is grounded in 
the fluorescence of aromatic amino acid residues, such as tryptophan and tyrosine.[154] 
These residues fluoresce when excited with light in the 270-300 nm wavelength 
range.[155] The emission spectrum of each is dependent on the local environment of the 
given residue.[156] Tryptophan is particularly sensitive; the emission spectra is red-shifted 
as the side group is exposed to a more polar solvent environment.[157] This technique can 
be useful for exploring tertiary structure changes of proteins. 
For investigation of protein secondary structure, one technique is to employ circular 
dichroism (CD) spectroscopy. The principle effect in CD is the absorbance of variable 
wavelength polarized light by chiral structures within a protein.[158] Typical protein 
secondary structure can be described as a combination of alpha helices, beta sheets, and 
random coils. Each of these motifs have absorb polarized light at signature wavelengths. 
When a protein is probed with polarized light, an absorbance spectrum is acquired. This 
spectrum can then be deconvoluted to determine the proportion of each secondary structure 
the protein is composed of.[159] Therefore, a protein can be analyzed with CD under 
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various conditions to monitor whether or not there are structural changes as well as provide 







3.1 Aim 1: Screen microneedle patch formulations and drying conditions 
to preserve dry influenza vaccine activity 
Influenza subunit vaccine can be formulated such that it can retain activity during 
air drying and during subsequent storage. This aim involved the screening of buffers and 
formulation excipients to stabilize commercial influenza subunit vaccine during drying and 
storage at ambient and elevated temperatures. Isolating different categories of formulation 
excipient allowed for examination of parameters that have an effect on vaccine stability 
during drying.  
 
3.2 Aim 2: Test stability and immunogenicity of influenza vaccine in 
microneedle patches 
The incorporation of influenza vaccine into suitably formulated microneedle 
patches causes minimal vaccine activity loss through long-term storage outside of the cold 
chain, and these patches remain immunogenic. Successful formulations developed in Aim 
1 were utilized to produce dissolving polymer microneedle patches with influenza vaccine. 
These patches were produced and stressed under various conditions they could possibly be 
exposed to once commercialized. A mouse model was also used to ensure aged patches 
retain immunogenicity. 
 
3.3 Aim 3: Provide insights into mechanisms of influenza vaccine activity 
loss during drying 
Subunit influenza vaccine loses activity predominantly due to aggregation, which 
can be inhibited by effective formulations. Influenza vaccine was dried and examined by 
various analytical techniques to monitor changes at the vaccine particle and protein level. 
These techniques gave further insights into the stability data from earlier work. 
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CHAPTER IV 
SCREEN MICRONEEDLE PATCH FORMULATIONS AND 




Influenza is a potentially life-threatening infectious disease that causes up to 5 
million cases of severe illness worldwide during seasonal epidemics, while up to 500,000 
people die from the disease each year.[160] Annual vaccination against influenza is 
recommended by the Centers for Disease Control and Prevention (CDC; Atlanta, GA) for 
everyone 6 months of age and older.[161] The influenza virus is a spherical lipid 
membrane-enveloped virus. One of its 11 proteins[2] is a spike protein, hemagglutinin 
(HA), which is the influenza vaccine’s primary antigenic protein.[161] This study was 
conducted using an inactivated purified subunit influenza vaccine where HA and 
neuraminidase (NA) are in rosette form. 
Despite the wide availability of a relatively low-cost vaccine, seasonal influenza 
vaccination coverage for adults in the United States hovers around just 40%.[162] Two 
reasons for the low vaccination coverage are patients’ needle phobia and inconvenience of 
travelling to a healthcare setting to receive the vaccine.[163] Currently, the most common 
route of influenza vaccination is an intramuscular injection of an aqueous suspension of 
HA. This method has several drawbacks, such as a reliance on the cold-chain for 
transportation and storage, a possibility of needle-stick injuries, and patients’ needle 
phobia. There are other routes of delivery such as nasal delivery and intradermal injection, 
which are used in recently approved products and also require cold-chain storage, 
administration by healthcare personnel and delivery methods that many people find 
unpleasant.[161] 
We and others have proposed the use of microneedle patches for influenza 
vaccination[68, 164-167] because of the previously demonstrated benefits of less patient 
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pain[49], improved immune response[167], and possible self-administration[168]. In this 
way, microneedle patches may enable scenarios where vaccine can be picked up over-the-
counter at stores or sent in the mail, so that people can vaccinate themselves and their 
families at home. An additional feature that would facilitate increased and simplified access 
to influenza vaccination using a microneedle patch would be reduced reliance on the cold-
chain for transportation and storage, thus allowing vaccines to be stockpiled more easily 
and transported to vaccine recipients. Therefore, the goal of this study is to develop 
thermostable microneedle patch formulations that can be partially or completely removed 
from the cold chain. 
Much knowledge about preserving vaccines in a dried state comes from the area of 
lyophilization.[169] The vaccine antigen is typically formulated in the liquid state with 
various excipients such as buffer salts, bulking agents, and cryoprotectants, and then 
freeze-dried to form a solid powder. One common approach to vaccine stabilization is to 
incorporate the vaccine into an amorphous sugar glass. This approach has been taken by a 
number of investigators to stabilize influenza HA in the dry state by optimizing pH, 
excipient composition, drying method, and other parameters.[20] Previous work has shown 
that HA can be stabilized during air drying onto microneedles with sugars such as trehalose 
and methylcellulose [170, 171]. However, we also showed that the inclusion of surfactant, 
while useful for coating metal microneedles, leads to matrix crystallization and HA activity 
loss.[172] While sugars are commonly used stabilizing excipients other compounds, such 
as amino acids, have been examined as well.[169] 
Guided by this previous work, in this study we determined the effect of formulation, 
drying, and storage conditions on the stability of a licensed sub-unit influenza vaccine 
during the manufacturing of microneedle patches. Initial screening was carried out by 
drying vaccine formulations suitable for microneedle patch fabrication and screening them 
for vaccine stability, which was followed by further formulation composition optimization 
and long-term stability testing. 
4.2 Methods  
4.2.1 Vaccine and reagents 
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 Monovalent vaccine stocks were generously provided by Novartis Vaccines 
and Diagnostics (Cambridge, MA). All studies were conducted using a monovalent stock 
of B/Brisbane/60/2008 influenza antigen. All excipients were received from Sigma-
Aldrich (St. Louis, MO), except for sodium heparin salt (Polysciences, Warrington, PA) 
and bovine serum albumin (EMD Millipore, Darmstadt, Germany). 
4.2.2 Formulations 
Vaccine stock solutions were received in phosphate-buffered saline (PBS). 
Monovalent stock of B/Brisbane/60/2008 received at a concentration of 360 µg/mL was 
buffer-exchanged using Vivaspin 500, 100 kDa MWCO or Vivaspin 20, 10 kDa MWCO 
centrifuge filters (Sartorius AG, Göttingen, Germany). Vaccine was concentrated at least 
10-fold using the filters, then diluted with the desired buffer. This process was repeated 2-
3 times. Finally, the same buffer was used to adjust the vaccine to the appropriate 
concentration for experiments, which was 60 µg/mL, as determined by ELISA. All buffers 
were prepared at 300 mosmol/L and adjusted with KOH or HCl to pH 7.0 - 7.4.  
To formulate vaccine, dry excipients were weighed and placed into Type 1 glass 
vials with fused inserts (ChemGlass, Vineland, NJ) or Type 1 glass vials (Wheaton, 
Millville, NJ), to which buffer-exchanged vaccine stock solution was added. All 
formulations contained 1% w/v 250 kDa sodium carboxymethyl cellulose (NaCMC). In 
the study on the effect of surfactant on vaccine stability, each surfactant was added so that 
the concentration was 50% higher than its critical micelle concentration (see Table 4.1 in 
Supporting Information). All formulations contained a total stabilizer excipient 
concentration of either 10% or 15% w/v, where the concentration was split amongst up to 
four compounds, unless the stabilizer was not soluble to the desired level, in which case 
the concentration of the stabilizer was its solubility limit at 25°C. 
4.2.3 Vaccine stability screening experiments 
To increase the throughput of formulation screening, drops of vaccine solution were 
dried on surfaces representative of coated metal microneedles or dissolving polymer 
microneedles. To simulate a metal microneedle drying surface, 6 mm-diameter circular 
“chips” were cut from sheets of Type 301 stainless steel (McMaster, Atlanta, GA). To 
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simulate the drying surface of dissolving microneedle molds, a thin film of Sylgard 184 
(Dow Corning, Midland, MI) was cured, from which 6 mm-diameter circular chips were 
removed with a hammer punch. Onto these surfaces were placed approximately 2 µL 
droplets of formulated vaccine solution at a concentration of approximately 100 µg/mL. 
Droplet weights were recorded on a Sartorius SE2 Ultra Micro Balance (Sartorius AG) for 
normalization to account for different actual masses administered in each droplet. The 
vaccine was allowed to dry at 15 – 25% relative humidity without added convection before 
chips were packaged in aluminum pouches (Oliver-Tolas Healthcare, Grand Rapids, MI) 
and sealed with an impulse heat-sealer (AIE-300, American International Electric, 
Industry, CA). All samples were stored with desiccant (Hammond Drierite, Xenia, OH), 
unless otherwise noted. Chips were then stored for up to 182 days in Model 6020 
environmental test chambers maintained at 5°C, 25°C or 40°C  (Caron, Marietta, OH). 
Vaccine activity remaining was calculated by comparing the dried sample to a positive 
control of similarly prepared vaccine that was not dried to account for any changes during 
formulation. 
4.2.4 ELISA assay 
Reconstituted vaccine samples were assayed for hemagglutinin activity using a 
sandwich enzyme-linked immunosorbent assay (ELISA). Polyclonal, strain-specific 
antibodies were received from the Center for Biologics Evaluation and Research (CBER) 
of the Food and Drug Administration (FDA; Silver Spring, MD). Antibodies were 
conjugated to horseradish peroxidase with a Lightning Link conjugation kit (Innova 
Biosciences, Cambridge, UK). Unformulated vaccine stock was serially diluted in 
phosphate-buffered saline with 0.5% Tween-20 (PBST) and used as a reference standard 
curve. After the prescribed storage time, chips were placed into PBS so that the dried 
vaccine and excipients were redissolved. This solution was run parallel to the reference 
standard curve on an Immulon 2HB 96-well microplate (Thermo Scientific, Waltham, 
MA). The microplate was washed 3 times between each step with PBST with 3% w/v 
bovine serum albumin. The HRP substrate reaction involved SureBlue Reserve TMB 
solution (KPL, Gaithersburg, MD), which was stopped with TMB Stop Solution (KPL). 
The microplate absorbance at 620 nm was read using an iMark plate reader (BioRad, 
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Hercules, CA). The standard curve was fit to a four-parameter function using the 
Microplate Manager 6 software (BioRad). HA activity is presented as the percent of HA 
activity remaining for dried chip samples compared to liquid control solutions.  
4.2.5 Statistics 
 All statistics were calculated using MiniTab software version 17 (MiniTab, State 
College, PA). All listed averages represent the arithmetic mean of the tested samples. 
Comparisons within individual samples were performed using an unpaired t-test with a 
significance cutoff of p<0.05. For comparisons between three or more samples, a one-way 
ANOVA was used or the data were fit to a general linear model, depending on the number 
of parameters varied, to determine significance. 
 
4.3 Results 
4.3.1 Drying time/temperature and buffer salts 
During microneedle patch manufacturing, a vaccine solution is typically dried on a 
microneedle surface or in a microneedle mold. To assess vaccine HA activity loss during 
this drying process, we dried solutions of B/Brisbane/60/2008 influenza vaccine on 
stainless steel chips to simulate manufacturing of metal microneedles coated with vaccine 
and on PDMS chips to simulate manufacturing of dissolving polymer microneedles in 
molds. The vaccine was formulated with NaCMC (to increase viscosity), trehalose (to help 
stabilize the vaccine during drying, as shown in previous studies[170]) and one of four 
different buffer salts. Drying was performed at 4°C, 25°C and 40°C for 60, 20 and 7 min, 
respectively. Each chip was allowed to dry at the designated temperature until the sample 
was “dry,” as determined by no further loss of mass due to water evaporation, i.e., 
equilibration with the surrounding air with humidity of 15 – 25% (data not shown). Upon 
drying, each sample was reconstituted and assayed for binding activity by ELISA.  
As shown in Figure 4.1, HA activity loss varied approximately from 0% to 50%, 
depending on vaccine formulation and drying conditions. Drying on stainless steel lead to 
more activity loss when compared to drying on PDMS (general linear model, p < 0.001). 
Choice of buffer salt also affected activity loss, where PBS performed the worst, and 4-(2-
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hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) and ammonium acetate retained 
more vaccine activity compared to potassium diphosphate (general linear model, p < 0.001 
and p < 0.01, respectively). Additional analysis showed that different drying temperatures 
(and thus different drying times, since drying was slower at lower temperature) had a 
significant effect on vaccine stability also (general linear model, p < 0.001), but no 
statistical difference was found when drying vaccine in ammonium acetate on PDMS at 
any temperature tested (ANOVA, p > 0.85). Based on these findings, we carried out the 
remaining experiments using vaccine solution buffer-exchanged into ammonium acetate 
buffer (pH 7.0) and dried on PDMS at room temperature. 
 
 
Figure 4.1. Effect of formulation buffer, drying temperature and drying substrate on 
HA activity after drying influenza trehalose was dried on (A) stainless steel (SS) or 
(B) polydimethylsiloxane (PDMS) chips at 4°C, 25°C or 40°C and assayed for HA 
activity after 24 h. PBS = phosphate-buffered saline; HEPES = 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid; K2HPO4 = potassium phosphate dibasic; AmAc = 
ammonium acetate. HA activity is shown as a percentage of concentrated stock 
vaccine solution after buffer exchanging to the respective vaccine on chips until “dry”. 
Vaccine (B/Brisbane/60/2008) formulated with 15% w/v buffer. Data represent 
averages of n = 6 replicates, with standard deviation bars shown. 
 
4.3.2 Surfactants 
Surfactants are often included in formulations used to coat microneedles.[64] The 
effects of including surfactants in the vaccine solution formulation were therefore 
examined by choosing representative surfactants from several categories, including 
cationic, anionic, zwitterionic and non-ionic. The concentration of each surfactant was 
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chosen to be 50% higher than its critical micelle concentration (see Table 4.1). First, the 
effect of preparing liquid vaccine solutions containing surfactants was assessed, which 
showed that the addition of surfactant to the liquid formulations reduced HA activity in 
certain cases by up to ~50% (Figure 4.2). Then, the effect of drying these formulations was 
assessed. We found that there was no significant further loss of HA activity due to the 
drying in most cases (Figure 4.2).  
 
 
Figure 4.2. Effect of surfactant on HA activity after drying influenza vaccine on 
PDMS or stainless steel chips at 25°C until “dry”. Vaccine (B/Brisbane/60/2008) was 
formulated with 15% w/v trehalose in ammonium acetate buffer. Asterisk (*) 
represents significant loss of HA activity in the liquid formulation containing 
surfactant compared to vaccine stock solution (Student’s t-test, p < 0.05). Hash (#) 
represents significant loss of HA activity in the dried formulation compared to the 
liquid formulation containing surfactant (Student’s t-test, p < 0.05). HA activity is 
shown as a percentage of activity of concentrated stock vaccine solution with the 
corresponding surfactant. Data represent averages of n = 6 replicates, with standard 
deviation bars shown. Surfactants and their critical micelle concentrations can be 









Figure 4.3. Effect of stabilizing excipients on HA activity after drying influenza 
vaccine on PDMS chips and storing with desiccant for 24 h at room temperature 
(25°C). Vaccine (B/Brisbane/60/2008) was formulated with individual excipients at a 
concentration of 15% in ammonium acetate buffer (See Table 4.2 for key to excipient 
list). Excipients had a positive effect (i.e., HA activity was significantly greater than 
the dried, unformulated vaccine indicated by the gray bar on the far right; Student’s 
t-test p < 0.05), no significant effect (p > 0.05) or a negative effect (p < 0.05). HA 
activity is shown as a percentage of concentrated stock vaccine solution. Data 
represent averages of n = 6 replicates, with standard deviation bars shown (Student’s 











SDS (sodium dodecyl sulfate) 8
CTAB (cetrimonium bromide) 1
CHAPS (3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate) 6
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Table 4.2. Key to vaccine formulation excipients found in Figure 4.3. 
 
 
Although surfactants did not generally affect HA stability during drying, the 
surfactants did generally reduce HA activity in the solution state before drying and previous 
studies have shown that surfactants can damage influenza vaccine during extended storage, 
possibly due to direct effects on the vaccine, such as solubilization of the viral 
membrane[174], or indirect effects on the vaccine, such as increased crystallization of 
formulation components[172]. For this reason, further experiments were performed 
without surfactant in the formulation. 
4.3.3 Stabilizer screening 
Our next step was to screen excipients that further stabilize HA activity during 
drying. Formulated vaccine was dried on PDMS chips and stored for 24 hours at room 
temperature with desiccant. As shown in Figure 4.3, there was a broad range of effects, 
spanning from almost complete loss of activity to almost complete retention of activity. 
These HA activity levels were compared to that of vaccine that was dried in the absence of 
Formulation # Stabilizer Activity remaining Formulation # Stabilizer Activity remaining
1 maltodextrin 4 98% 32 lysine 40%
2 arginine 91% 33 sodium phosphate 40%
3 trehalose 89% 34 valine 40%
4 maltose 87% 35 threonine 39%
5 histidine 85% 36 galactose 39%
6 calcium heptagluconate 85% 37 alanine 37%
7 maltodextrin 13 85% 38 methionine 37%
8 sucrose 82% 39 proline 35%
9 glucose 82% 40 mannitol 34%
10 heparin 81% 41 human serum albumin 2 34%
11 raffinose 80% 42 glutamine 34%
12 myo-inositol 77% 43 human serum albumin 1 32%
13 lactose 77% 44 tryptophan 32%
14 sorbitol 76% 45 tyrosine 32%
15 arabitol 75% 46 serine 31%
16 fructose 72% 47 bovine serum albumin 31%
17 γ-cyclodextrin 70% 48 creatine 30%
18 potassium gluconate 62% 49 leucine 30%
19 adonitol 60% 50 potassium sulfate 29%
20 xylitol 58% 51 sodium succinate 29%
21 sodium thiosulfate 57% 52 isoleucine 29%
22 asparagine 55% 53 ethyl lactate 24%
23 2-hydroxypropyl-β-cyclodextrin 55% 54 phenylalanine 23%
24 Tris 54% 55 arabinose 21%
25 sodium citrate 53% 56 potassium phosphate 16%
26 dulcitol 53% 57 xylose 14%
27 potassium citrate 50% 58 potassium sulfite 9%
28 ovalbumin 47% 59 cysteine 8%
29 glycine 47% 60 glycerol 4%
30 methyl glucoside 43% 61 sodium thioglycolate 4%
31 β-cyclodextrin 42%
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excipients (i.e., the bar on the far right of the graph) and classified into three categories: 
compounds that stabilized the vaccine (i.e., greater stability than the unformulated control, 
Student’s t-test, p < 0.05), compounds that had no significant effect (p > 0.05), and 
compounds that destabilized the vaccine (p < 0.05). Most of the compounds that stabilized 
HA activity were carbohydrates along with a few amino acids. 
To identify formulations that stabilize HA not only during drying, but also during 
subsequent storage, dried vaccine samples were stored for 1 week at 40°C as a second level 
of screening. Because there can be improved effects when multiple stabilizers are used 
together[175], we selected the best stabilizers from the initial screen and assessed their 
effect alone or in pairwise combination with each other. This second, more-stringent screen 
identified individual stabilizers that continued to be effective and identified stabilizer 
combinations that were effective as well (Figure 4.4). In most cases, stabilizer 
combinations were no better than at least one of the individual stabilizers, except for two 
combinations (Figure 4.4).  
Based on the one-week screening study, vaccine formulations were prepared using 
the top five stabilizers, as well as each two-stabilizer combination of these excipients, dried 
and stored at 40°C for up to one month. While most formulations were stable up to one 
week, most of them also lost substantial HA activity at one month (Figure 4.5). Three 
combinations, however, had no significant activity loss during the one month of storage. 






Figure 4.4. Effect of combinations of stabilizing excipients on HA activity after drying 
influenza vaccine on PDMS chips and storing with desiccant for one week at 40°C. 
Vaccine (B/Brisbane/60/2008) was formulated with either one or two stabilizing 
excipients at a total stabilizer concentration of 15% w/v in ammonium acetate buffer 
(See Table 4.3 for key to excipient list). In each set of bars, the first bar shows HA 
activity for the combination formulation, the second bar shows HA activity for 
formulation with just the first stabilizing excipient and the third bar shows HA 
activity for formulation with just the second stabilizing excipient. Asterisk (*) 
indicates combination-excipient formulations with significantly higher HA activity 
compared to either associated individual-excipient formulations (Student’s t-test, p < 
0.05). HA activity is shown as a percentage of concentrated stock vaccine solution. 



























Figure 4.5. Effect of stabilizing excipients on HA activity after drying influenza 
vaccine on PDMS chips and storing with desiccant for up to one month at 40°C. 
Vaccine (B/Brisbane/60/2008) was formulated with individual or pair-wise 
combinations of stabilizing excipients at a total stabilizer concentration of 15% w/v 
in ammonium acetate buffer. HA activity is shown as a percentage of concentrated 
stock vaccine solution. T= trehalose, S = sucrose, A = arginine, H = calcium 
Formulation # Stabilizer 1 Stabilizer 2
1 maltodextrin lactose
2 maltodextrin sodium thiosulfate
3 maltodextrin trehalose




8 arginine sodium thiosulfate
9 arginine trehalose
10 arginine sodium citrate
11 arginine sorbitol
12 sorbitol lactose
13 sorbitol sodium thiosulfate
14 sorbitol trehalose
15 sorbitol sodium citrate
16 sodium lactose
17 sodium sodium thiosulfate
18 sodium trehalose
19 trehalose lactose
20 trehalose sodium thiosulfate
21 sodium thiosulfate lactose
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heptagluconate, M = maltodextrin 13, MB = monobulk. Asterisk (*) indicates no 
statistically different HA activity amongst the three time points (Student’s t-test, p < 
0.05). Bars represent averages of n = 5 replicates; with standard deviation bars shown. 
4.3.4 Long-term stability of chips 
Using the optimal vaccine formulations identified in the one-month screen, we 
carried out a six-month screen using those excipients in pairwise combination at 
formulation ratios of 90:10, 50:50, and 10:90, as well as combinations of three excipients 
and all four excipients combined in equal amounts (Figure 4.6). Unformulated vaccine lost 
nearly all of its activity within the first month of testing. All the formulations tested in this 
study were generally stable for the eighteen months of study without an effect of stabilizer 
ratio. At the eighteen-month time point, none of the formulations showed significant loss 
in HA activity relative to day 0 (Student’s t-test, p < 0.05). 
 
Figure 4.6, Effect of stabilizing excipient formulation on hemagglutinin (HA) activity 
after drying influenza vaccine on PDMS chips and storing with desiccant for up to 
twelve months at 40°C. Vaccine (B/Brisbane/60/2008) was formulated with 
combinations of two, three, or four stabilizing excipients at a total stabilizer 
concentration of 10% w/v in the vaccine casting solution. For the two-stabilizer 
combinations, the concentration ratio is shown, where the first number corresponds 
to the relative content of the first excipient listed below it on the x axis. The three-way 
and four-way formulation had equal amounts of each excipient. T = trehalose, S = 
sucrose, A = arginine, H = sodium heptagluconate. HA activity is expressed as a 
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percentage of HA activity in the liquid casting solution. Data represent averages of n 
= 12 replicates, with standard deviation bars shown. 
 
4.3.5 Packaging humidity 
To examine the effect of humidity during storage, several single-excipient 
formulations were dried on PDMS chips and stored at 40°C for up to 16 weeks in aluminum 
pouches with either desiccant, to maintain a humidity approaching zero, or conditioned 
silica gel pouches, to maintain a relative humidity of 70%. As seen in Figure 4.7, desiccated 
samples were generally stable, whereas samples stored at elevated humidity rapidly lost 
HA activity. 
 
Figure 4.7. Effect of humidity on HA activity after drying influenza vaccine on PDMS 
chips and storing with desiccant for up to 16 weeks at 40°C. Vaccine 
(A/Brisbane/59/2007) was formulated with trehalose, sucrose or maltodextrin at a 
concentration of 10% w/v in ammonium acetate buffer. Chips were stored with either 
desiccant (dry) or silica gel that had been conditioned to maintain 70% relative 
humidity (humid). Asterisk (*) indicates a significant change in HA activity over time 
(ANOVA, p < 0.05). HA activity is shown as the mass of active HA. Data represent 




This study seeks to develop formulations towards a thermostable microneedle patch 
for influenza vaccination. Through a series of screening and optimization studies to 
develop formulation compositions and manufacturing parameters that enhance 
thermostability of the HA antigen in influenza vaccine, we developed microneedle patch 
formulations that protected the influenza vaccine antigen during eighteen months of storage 
at an elevated temperature.  
In the study design, we expected two timescales of HA activity loss. The first is the 
initial drying phase where the liquid formulation is allowed to air-dry over the course of 
minutes to hours, thereby stressing the antigen as water is removed. The second timescale 
occurs over days to months, as the dried antigen and its matrix can slowly change during 
storage. The study plan therefore included initial screening of formulations and 
manufacturing conditions that protected the vaccine during the initial drying phase, and 
then built on those results to further develop formulations that protected the vaccine during 
storage. 
The optimization was carried out on “chips” that simulated the manufacturing 
process without the need to go through the more laborious process of making actual 
microneedle patches. Advantages of this approach included ease of operation, control of 
antigen loading, and reduced amount of antigen required per test. The PDMS chips were 
representative of PDMS molds used during manufacturing of dissolving 
microneedles[176] and the stainless steel chips were representative of the metal 
microneedles used during manufacturing of coated microneedles. Based on the first set of 
experiments, we identified drying on PDMS at room temperature using ammonium acetate 
buffer as our baseline operating condition. We chose PDMS as the drying substrate because 
HA activity was more stable on PDMS than on stainless steel, and because we are primarily 
interested in making dissolving microneedle patches that generate no sharps waste, which 
are manufactured using PDMS molds. We chose room temperature, because there was not 
a significant effect of temperature on HA activity when ammonium acetate was the buffer, 
and room temperature is simpler to implement than cooled or heated drying, and is faster 
than drying at low temperature. Although HEPES buffer performed similarly well, we 
chose ammonium acetate buffer because it maintained HA activity during drying and, as a 
volatile buffer, it will partially evaporate during drying, thereby leaving fewer 
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crystals.[177] PBS performed the worst, perhaps because of pH drops when dibasic 
phosphate precipitates before monobasic phosphate.[83] 
Surfactants were found to destabilize HA activity, especially in liquid formulation 
before drying. Previous work has further shown that surfactants can cause crystallization 
in the microneedle coating matrix during storage and cause damage to HA activity.[172] 
We therefore chose not to include surfactants in our formulation, since they are not 
typically needed when molding dissolving microneedles, although they are often used 
when coating metal microneedles.[66] 
Using these baseline operating conditions, we screened a large number of 
excipients selected to stabilize HA activity during drying and subsequent storage. 
Candidate excipients were selected from the literature and past data from our laboratory 
showing stabilization of HA and other proteins and vaccines, included conventionally used 
stabilizers as well as other compounds not well known for their stabilizing properties. We 
found that approximately 45% of the excipients tested provided significant stabilizing 
effects, almost 20% destabilized HA and the remainder had no significant effect when 
compared to drying the vaccine with no additional excipients. The large majority of 
successful stabilizers were carbohydrates, including small saccharides, polyols, and long-
chain polysaccharides. Two notable exceptions were the stabilizing amino acids, arginine 
and histidine. 
We next tested combinations of the best-performing stabilizers, some of which 
performed better than their individual excipient components. The best-performing 
formulations generally contained arginine and calcium heptagluconate either in pairwise 
combination or as components of formulations containing additional excipients as well, 
such as both trehalose and sucrose. Considering the stabilizer ratio of the formulation, we 
generally found among a set of two excipient combinations, a composition of 50:50 
retained the most antigen activity. 
The development of a thermostable influenza vaccine patch could facilitate greater 
influenza vaccination coverage during both seasonal and pandemic influenza scenarios. 
The cold chain contributes substantially to the cost of storing and transporting vaccine 
doses.[178, 179] In addition, thermostability is important to our long-term vision of a self-
administered microneedle patch for influenza vaccination,[168] where vaccine could be 
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stored on non-refrigerated shelves in the pharmacy and could be mailed to patients at home 
without ice packs. 
4.5 Conclusion 
This study had the objective to develop a thermostable microneedle patch for 
influenza vaccination. Initial studies focusing on maintaining stability during the drying of 
influenza vaccine associated with microneedle patch manufacturing determined that HA 
activity was higher after drying on PDMS than on stainless steel, was only sometimes 
significantly affected by drying temperature at 4°C, 25°C or 40°C, was more effectively 
stabilized by ammonium acetate and HEPES buffers than phosphate-based buffers, and 
was destabilized by addition of surfactants. Subsequent studies assessed the ability of 60 
excipients to stabilize HA activity during drying and subsequent storage at elevated 
temperature. The best excipients, and excipient combinations, were then identified as those 
that maintained HA activity for up to eighteen months at 40°C when stored with desiccant. 
The best performing stabilizer combination was arginine/heptagluconate. This work will 
be utilized to further develop a dissolving microneedle patch that can remain independent 
of the cold chain. We conclude that the formulations developed here may enable 
development of a thermostable microneedle patch for influenza vaccination to improve 
future coverage during seasonal and pandemic vaccination.  
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TEST STABILITY AND IMMUNOGENICITY OF INFLUENZA 
VACCINE IN MICRONEEDLE PATCHES  
 
5.1 Introduction 
Influenza is estimated to cause up to five million illnesses and five hundred 
thousand deaths each year.[160] Annual seasonal influenza vaccination is recommended 
by the Centers for Disease Control and Prevention[161], and more than 148 million people 
received the vaccine in the United States during the 2014-15 influenza season.[180] As a 
result, there is significant cost, complex logistics and vaccine spoilage due to the need to 
distribute and store the vaccine in the cold-chain .[181] Elevated temperatures as well as 
exposure to freeze-thaw cycles have been shown to adversely affect the stability of seasonal 
influenza vaccine.[130] 
One method to maintain the activity of vaccines, or proteins in general, is 
lyophilization. For many proteins, preservation in a dry state enables storage for longer 
time or without refrigeration.[182] In a dry state, protein mobility is greatly reduced,[183] 
and there is less water available for many decomposition reactions.[184] Lyophilized 
biopharmaceuticals must still be reconstituted with an appropriate diluent and administered 
via a hypodermic needle and syringe. All current influenza vaccines are stored and 
delivered in the liquid state and also require the use of the cold-chain. The cold-chain can 
cost hundreds of million dollars per vaccine program[181], thus an influenza vaccine stable 
at room temperature could be of significant financial benefit. 
We and others are developing microneedle patches for vaccination against 
influenza and other diseases.[65, 70, 140, 171, 185, 186] Microneedle patches contain an 
array of sub-millimeter projections composed primarily of water-soluble sugars and 
polymers that encapsulate a payload of drug or vaccine.[176] Since these patches hold the 
vaccine in a dry state, once produced, microneedle patches can maintain stability similar 
to lyophilized vaccine. To achieve this stable state, formulation excipients must be 
optimized to maintain vaccine activity during manufacturing and subsequent storage. 
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During manufacturing, a vaccine and excipient mixture is cast and dried into molds and 
allowed to dry, which can damage the vaccine. There has been work to develop formulation 
strategies to stabilize influenza vaccine during microneedle fabrication. For example, 
silk[187] and trehalose[139] have been incorporated into microneedle formulations to 
stabilize influenza vaccine during drying. Aside from stability enhancement, microneedles 
could increase the acceptance of vaccine administration[168] and improve the immune 
response in recipients[69, 188] . 
Formulation excipients that function as lyoprotectants of proteins are often small 
sugars.[111, 179, 189, 190] There are thought to be two different, yet possibly 
simultaneous, mechanisms by which sugars and polyols maintain protein stability in a dried 
state.[179, 189] One is the formation of an amorphous sugar glass phase with such a high 
viscosity that molecular mobility is severely restricted.[191] This restricted mobility 
decreases kinetics of possible degradation pathways, both chemical and physical.[183] The 
other mechanism is the replacement of removed water molecules’ hydrostatic interactions 
by hydroxyl groups from the sugars,[192] which is needed because water molecules form 
a stabilizing hydration shell around proteins in solution.[193] Polysaccharides, such as 
inulin[194], and amino acids, such as arginine[119], have also been used to stabilize 
proteins, due also to advantageous excipient/protein interactions and the creation of a 
favorable dry matrix. 
In a previous study, we screened 61 different formulation excipients and some of 
their combinations to find three pairwise excipient combinations that were especially 
promising at stabilizing a trivalent subunit influenza vaccine: trehalose/sucrose, 
sucrose/arginine, and arginine/heptagluconate.[195] In this study, we further examined 
these formulations for stability at 25°C and 40°C over periods up to 18 months and during 
environmental stresses such as exposure to 60°C for four months, multiple freeze-thaw 
cycles, and electron beam irradiation.  
  
5.2 Methods  
5.2.1 Vaccine and reagents 
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Monovalent vaccine stocks were generously provided by Novartis Vaccines and 
Diagnostics (Cambridge, MA). Studies with monovalent vaccine dried on chips and in 
microneedle patches stored for eighteen months utilized B/Brisbane/60/2008 influenza 
antigen, while for studies testing stability at 60°C, freeze conditions, and irradiation 
utilized A/Brisbane/10/2010 (H1N1) influenza antigen. Studies with trivalent vaccine 
utilized B/Brisbane/60/2008, A/Brisbane/59/2007 (H1N1) and A/Victoria/210/2009 
(H3N2) influenza antigens. All excipients were received from Sigma-Aldrich (St. Louis, 
MO). 
5.2.2 Vaccine formulation 
Vaccine stock solutions were received in phosphate buffered saline (PBS). To 
buffer exchange into ammonium acetate buffer, monovalent stock solutions of the desired 
strain was concentrated at least 10-fold using Vivaspin 500, Vivaspin 20, or Vivaspin 2 
centrifuge filters with molecular weight cutoffs of 100, 10, and 3 kDa, respectively 
(Sartorius AG, Göttingen, Germany) and then diluted with 150 mM ammonium acetate 
buffer. This process was repeated 2-3 times. Finally, the ammonium acetate buffer was 
used to adjust the vaccine to the appropriate concentration for experiments. 
To formulate vaccine for casting onto molds, dry excipients were weighed and 
placed into Type 1 glass vials (Wheaton, Millville, NJ), to which buffer-exchanged vaccine 
stock solution was added. All formulations contained 1% w/v 250 kDa sodium 
carboxymethyl cellulose (NaCMC). All formulations contained a total stabilizing excipient 
concentration of 10% w/v, where the concentration was split amongst up to four 
compounds. 
5.2.3 Vaccine stability testing in microneedle patches 
Microneedle patches were prepared using two different casting solutions. First, a 
PDMS mold in the shape of the microneedle patch was prepared, using methods described 
previously.[196] The vaccine casting solution consisted of influenza vaccine, 1% w/v 
NaCMC, and 10% w/v of stabilizer in 150 mM ammonium acetate buffer. The matrix 
casting solution consisted of polyvinyl alcohol (PVA), sucrose, and water in a mass ratio 
of 8:6:15. To make microneedle patches, vaccine casting solution was placed on a mold to 
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fill the microneedle cavities with the aid of vacuum. Excess vaccine solution was removed 
from the mold surface with a flat blade. The vaccine casting solution was then allowed to 
dry into the tips of the microneedle mold cavities under vacuum. Next, matrix casting 
solution was placed on the mold and allowed to dry under vacuum, thereby forming a 
complete microneedle patch. Each patch was then stored in a desiccator at room 
temperature (~21 - 25°C) for two days before demolding with Scotch tape (3M, St. Paul, 
MN). 
Demolded patches were packaged with desiccant in aluminum pouches and stored 
at a given temperature (i.e., 4°C, 25°C or 40°C) in stability chambers. For patches subjected 
to freeze-thaw cycles, each cycle consisted of two hours at -20°C followed by two hours at 
4°C. Patches subjected to electron-beam sterilization were irradiated using a 10 MeV (20 
kW) system at room temperature for a total exposure of 10 or 20 kGy. The nonirradiated 
controls were subjected to the same travel and storage conditions as the test samples. 
5.2.4 ELISA assay 
Reconstituted vaccine samples were assayed for hemagglutinin activity using a 
sandwich enzyme-linked immunosorbent assay (ELISA). Polyclonal, strain-specific 
antibodies were received from the Center for Biologics Evaluation and Research of the 
Food and Drug Administration (Silver Spring, MD). Antibodies were conjugated to 
horseradish peroxidase with a Lightning Link conjugation kit (Innova Biosciences, 
Cambridge, UK). Unformulated vaccine stock was serially diluted in PBS with 0.5% 
Tween-20 (PBST) and used to generate a reference standard curve. After the prescribed 
storage time, chips and microneedle patches were placed into PBST so that the dried 
vaccine and excipients were redissolved. This solution was run parallel to the reference 
standard curve on an Immulon 2HB 96-well microplate (Thermo Scientific, Waltham, 
MA). The microplate was washed three times between each step with PBST containing 3% 
w/v bovine serum albumin. The horseradish peroxidase (HRP) substrate reaction involved 
SureBlue Reserve TMB (3,3’,5,5’-tetramethylbenzidine) solution (KPL, Gaithersburg, 
MD), which was stopped with TMB Stop Solution (KPL). The microplate absorbance at 
620 nm was read using an iMark plate reader (BioRad, Hercules, CA). The standard curve 
was fit to a four-parameter function using the Microplate Manager 6 software (BioRad).  
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5.2.5 Immunization of mice 
Immunization of mice 
Groups of female BALB/c mice (n=8 per group), all 6-8 weeks of age, were 
immunized via either an intradermal (ID) injection at the base of the tail or by application 
of a microneedle patch to the back. In the first study, animals were vaccinated with 3.8 µg, 
2.8 µg, and 3.8 µg of H1N1, H3N2, and B strains, respectively, administered either by ID 
injection of fresh stock vaccine or using microneedle patches stored at 25 °C for 13 months. 
In the second study, animals were vaccinated with 1 µg, 0.6 µg, and 0.6 µg of H1N1, H3N2, 
and B strains, respectively, by ID injection of fresh stock vaccine, by ID injection of 
vaccine reconstituted from microneedle patches stored at 25 °C for 13 months or using 
freshly made microneedle patches. All patches were made using arginine and 
heptagluconate at a mass ratio of 50:50 as the stabilizers in the vaccine casting solution.  
Hair was removed one day prior to immunization using electric clippers and a 
depilatory cream (Nair; Ewing, NJ). Patches were applied by pressing the patch against a 
pinch of hair-free skin using the thumb and forefinger for 1 min. Adhesive on the patch 
backing held the patch in place for a further 20 min to ensure microneedle dissolution in 
the skin. Blood was drawn via the jugular vein at days 0, 14, and 28. Whole blood was then 
spun down in serum separation tubes (Becton Dickinson, Franklin Lakes, NJ) to collect the 
serum. 
5.2.6 Hemagglutination inhibition titers 
Production of influenza-specific antibodies was determined by hemagglutination 
inhibition (HAI) assay. Serum was treated with receptor-destroying enzyme (Denka 
Seiken, Tokyo, Japan) overnight at 37°C. Samples were then incubated at 56°C for 30 min 
before being incubated overnight with packed red blood cells at 4°C. After centrifugation, 
supernatant was collected, serially diluted in PBS, and mixed with separate strain-specific 
influenza viruses for 30 min. Finally, 0.5% chicken red blood cells was added. The 
reciprocal of highest dilution titer that prevented hemagglutination was read as the HAI 
titer. 
5.2.7 Electron beam irradiation 
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Electron beam irradiation was conducted by Synergy Health (Lima, OH) using a 
10MeV (20 kW) system, irradiated at 10 or 20 kGy. The irradiations were conducted at 
ambient temperatures. The nonirradiated controls were subjected to the same travel and 
storage conditions as the test samples.  
5.2.8 Statistics 
All statistics were calculated using Excel 2013 software (Microsoft, Redmond, 
WA). Reported averages represent the arithmetic mean of the tested samples, except for 
HAI titers, which are presented as the geometric mean titer for each group. Seropositivity 
was considered to be an HAI titer greater than or equal to 40. Comparisons between 




5.3.1 Stability of influenza vaccine patches over time at room temperature 
Guided by the screening results generated on chips showing that all of the two-, 
three- and four-way combinations of stabilizers effectively stabilized the vaccine, we made 
microneedle patches containing monovalent vaccine using the three optimal two-way 
combinations and tested their stability during storage at 25°C for 18 months. These patches 
were made by first casting a vaccine solution containing the antigen and stabilizing 
excipients and, after drying, casting a matrix solution containing sucrose and PVA to fill 
any remaining space not occupied by the dried vaccine solution and to form the patch 
backing. Among the microneedle patches with two-way combinations of stabilizing 
excipients, only the arginine/heptagluconate formulation exhibited no significant loss of 
vaccine activity after 18 months (Fig. 5.1, Student’s t-test, p > 0.05).  
Using just the individual stabilizers showed that formulation with any of the 
saccharides resulted in no significant loss of vaccine activity after 18 months (Fig. 5.1, 
Student’s t-test, p > 0.05), but there was a significant decrease in vaccine activity at 18 
months when arginine was used as the only stabilizer (Fig. 5.1, Student’s t-test, p = 0.03). 
The unformulated vaccine also had no loss of activity after 18 months (Fig. 5.1, Student’s 
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t-test, p > 0.05). However, the patches using unformulated vaccine and vaccine formulated 
with the single stabilizers sucrose, arginine or heptagluconate had significant losses in 
activity during fabrication on Day 0 by comparison with vaccine activity in patches 
formulated with arginine-heptagluconate as a positive control (Fig. 5.1, Student’s t-test, p 
< 0.05). This is probably due to differences in vaccine stabilization associated with vaccine 
drying during patch fabrication. Comparison of these findings in microneedle patches to 
the previous findings on chips indicates that the excipients in the matrix casting solution 
used to make the microneedle patch backing provided additional stabilization.  
Based on these findings with monovalent patches, we assessed the stability of 
trivalent patches using the three two-way combinations of stabilizers. There was no 
significant change in vaccine activity for any of the three vaccine strains using the 
arginine/heptagluconate formulation after storage for 18 months at 25°C, as well as the 
H1N1 strain when formulated with trehalose/sucrose (Fig. 5.2, Student’s t-test, p > 0.05). 
There was also no noticeable change in the appearance of the patches after storage 
compared to freshly prepared patches (Fig. 5.3a-b). These findings further indicate the 




Figure 5.1. Effect of formulation on hemagglutinin (HA) activity after fabricating 
microneedle patches and storing with desiccant for up to 18 months at 25°C. 
Monovalent microneedle patches were fabricated with B/Brisbane/60/2008 influenza 
vaccine formulated with stabilizing excipients at a total concentration of 10% w/v in 
the vaccine casting solution. The two-stabilizer combinations contained equal 
amounts of each excipient. T = trehalose, S = sucrose, A = arginine, H = sodium 
heptagluconate. HA activity is shown as the mass of active HA in each patch. Data 
represent averages of n = 6 replicates, with standard deviation bars shown. 
 
 
Figure 5.2. Effect of formulation on hemagglutinin (HA) activity after fabricating 
microneedle patches and storing with desiccant for up to 18 months at 25°C. Trivalent 
microneedle patches were fabricated with A/Brisbane/59/2007 (H1N1), 
A/Victoria/210/2009 (H3N2) and B/Brisbane/60/2008 (B) influenza vaccine 
formulated with two-way combinations of stabilizing excipients at a ratio of 50:50 
with a total stabilizer concentration of 10% in the vaccine casting solution. T = 
trehalose, S = sucrose, A = arginine, H = sodium heptagluconate, * = data not 






Figure 5.3. Images of representative microneedle patches (A) immediately after 
production, (B) after storage at 25C for 18 months, (C) after storage at 60C for two 
months, and (D) after five freeze-thaw cycles. 
 
5.3.2 Immunogenicity of stored influenza vaccine patches 
To determine if the in vitro vaccine stability of microneedle patches correlated with 
in vivo immunogenicity, mice were immunized using microneedle patches containing 
trivalent influenza vaccine that had been stored for 13 months at 25°C and compared to ID 
injection of fresh vaccine. There was no significant difference in immune response to the 
H1N1 influenza strain between the mice immunized with a stored microneedle patch and 
by an ID injection (Fig 5.4a). Immune response to the H3N2 strain was higher for stored 
microneedle patches than ID injection (Fig. 5.4b). For both strains, all mice were 
seropositive after vaccination with stored microneedle patches, but only 50% – 70% were 
seropositive after ID vaccination (Fig 5.4c – 5.4d). However, immune responses to the B 
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strain of influenza could not be measured due to lack of access to the virus needed for the 
assay.  
The superior immune response of stored microneedle patch vaccination compared 
to ID vaccination may at first be surprising. However, comparison of fresh microneedle 
patch vaccination to ID vaccination similarly showed improved immune response after 
microneedle patch vaccination (Fig. 5.5), indicating that the superior response was not 
associated with storage, but was instead associated with the microneedle patch method of 
vaccination, which is consistent with prior literature[69, 197]. Moreover, ID injection of 
vaccine reconstituted from stored microneedle patches generated immune responses not 
significantly different from ID injection of fresh vaccine (Fig. 5.5), further suggesting that 
stored vaccine was as immunogenic as fresh vaccine and that improved immunogenicity 
was associated with microneedle patch administration.  
 
 
Figure 5.4. Immune responses of BALB/c mice immunized with trivalent influenza 
vaccine. Strain-specific hemagglutination inhibition (HAI) titers are represented as 
geometric means of n = 8 mice, with ± standard error of mean bars shown for (A) 
H1N1 and (B) H3N2 influenza vaccination. Asterisk (*) indicates a significant 
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difference in antibody titers (Student’s t-test, p < 0.05). Seropositivity data for (C) 
H1N1 and (D) H3N2 influenza vaccination are represented as the percentage of each 
experimental group that achieved an antibody titer of ≥40. Trivalent microneedle 
patches were fabricated with A/Brisbane/59/2007 (H1N1), A/Victoria/210/2009 
(H3N2) and B/Brisbane/60/2008 (B) influenza vaccine formulated with a two-way 
combination of arginine and heptagluconate each at a concentration of 5% w/v in the 
vaccine casting solution ID = intradermal vaccination, Stored patch = vaccination 
with a microneedle patch after storage at 40°C with desiccant for 13 months. Data 
from vaccination with B/Brisbane/60/2008 are not available due to technical 
limitations. 
 
Figure 5.5. Immune responses of BALB/c mice immunized with trivalent influenza 
vaccine. Strain-specific hemagglutination inhibition (HAI) titers are represented as 
geometric means of n = 8 mice, with ± standard error of mean bars shown for (A) 
H1N1 and (B) H3N2 influenza vaccination. Asterisk (*) indicates a significant 
difference in antibody titers (Student’s t-test, p < 0.05). Seropositivity data for (C) 
H1N1 and (D) H3N2 influenza vaccination are represented as the percentage of each 
experimental group that achieved an antibody titer of ≥40. Trivalent microneedle 
patches were fabricated with A/Brisbane/59/2007 (H1N1), A/Victoria/210/2009 
(H3N2) and B/Brisbane/60/2008 (B) influenza vaccine formulated with a two-way 
combination of arginine and heptagluconate each at a concentration of 5% w/v in the 
vaccine casting solution ID = intradermal vaccination, Fresh patch = vaccination with 
a microneedle patch, Reconstituted (ID) stored patch = intradermal vaccination using 
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a reconstituted microneedle patch after storage at 40°C with desiccant for 13 months. 
Data from vaccination with B/Brisbane/60/2008 are not available due to technical 
limitations. 
5.3.3 Stability of influenza vaccine patches at elevated temperature 
While microneedle patches stored at 25°C simulates vaccine storage in a climate-
controlled pharmacy or warehouse, we wanted to determine if microneedle patches 
remained stable at higher temperatures. Microneedle patches containing monovalent 
influenza vaccine were therefore stored at 60°C for four months. There was no significant 
loss of vaccine activity for these patches as a function of time (Fig. 5.6, ANOVA, p > 0.05) 
or in comparison to patches stored in parallel at 25°C (Fig. 5.6, ANOVA, p > 0.05). Visual 
inspection of the patches indicated minor discoloration of the patch after storage at 60°C, 
suggesting that patch excipients may have been affected (Fig. 5.3c). 
 
 
Figure 5.6. Stability of influenza vaccine in microneedle patches stored 60°C with 
desiccant for up to four months compared to patches stored at 25°C under identical 
conditions. Monovalent microneedle patches were fabricated with 
A/Brisbane/10/2010 influenza vaccine formulated with a two-way combination of 
arginine and heptagluconate each at a concentration of 5% w/v in the vaccine casting 
solution. Data from patches stored at 60°C are shown, as well as control patches which 
were stored at 25°C and tested simultaneously. HA activity is shown as the mass of 
active HA in each patch. Data represent averages of n = 6 replicates, with standard 






5.3.4 Stability of influenza vaccine patches after multiple freeze-thaw cycles 
Vaccines can be exposed to freeze-thaw cycles if stored without environmental 
controls or during poorly-controlled refrigeration. To address such conditions, microneedle 
patches containing monovalent influenza vaccine were subjected to five freeze-thaw 
cycles, alternating between -20°C and 4°C, over the course of 24 h, after which there was 
no significant change in vaccine activity compared to patches maintained at 25°C (Fig. 5.7, 
Student’s t-test, p = 0.95). Patches maintained at 4°C or at -80°C also had no significantly 
loss of activity compared to patches stored at 25°C (Fig. 5.7, Student’s t-test, p > 0.05). 
Interestingly, unformulated liquid vaccine subjected to identical freeze-thaw cycles also 
showed no loss in vaccine activity (Fig. 5.7, Student’s t-test, p = 0.88). The appearance of 
patches after the freeze-thaw cycles showed no apparent differences from fresh patches 
(Fig. 5.3d). 
  
Figure 5.7. Stability of influenza vaccine in microneedle patches subjected to five 
freeze-thaw cycles. Monovalent microneedle patches were fabricated with 
A/Brisbane/10/2010 influenza vaccine formulated with a two-way combination of 
arginine and heptagluconate each at a concentration of 5% w/v in the vaccine casting 
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solution. All samples were stored for a total of 24 hours. Freeze-thawed samples were 
subjected to five freeze-thaw cycles of 2 h each at 4°C followed by 2 h at -20°C. Patches 
stored at 25°C served as the positive control. Patches were also stored at 4°C and -
80°C for comparison. Finally, liquid vaccine was subjected to the same freeze-thaw 
cycles. Data represent averages of n = 6 replicates, with standard deviation bars 
shown. 
5.3.5 Stability of influenza vaccine patches after electron-beam sterilization 
Terminal sterilization of microneedle patches could provide cost savings relative to 
aseptic manufacturing. Microneedle patches containing monovalent influenza vaccine 
were therefore subjected to electron beam sterilization at two different radiation doses. 
Compared to untreated patches, there was no significant loss of vaccine activity at either 
radiation dose (Fig. 5.8, Student’s t-test, p > 0.05). Patch appearance after irradiation 
showed no apparent changes from fresh patches (image not available). 
 
Figure 5.8. Stability of influenza vaccine in microneedle patches exposed to electron 
beam irradiation. Monovalent microneedle patches were fabricated with 
A/Brisbane/10/2010 influenza vaccine formulated with a two-way combination of 
arginine and heptagluconate each at a concentration of 5% w/v in the vaccine casting 
solution. HA activity is shown as the mass of active HA in each patch. Data represent 






This work builds upon previous work that included a screen of microneedle 
formulation excipients to stabilize influenza vaccine.[195] The stability of dried vaccine 
on chips as well as in patches stored for up to 18 months at 25°C was reported in that work. 
The work reported here shows further evidence of stability when influenza vaccine was 
incorporated into dissolving microneedle patches and  maintained activity after storage at 
25°C for at least 18 months, 60°C for at least four months, five freeze-thaw cycles and 
electron beam irradiation. The ability to withstand this wide array of stressful conditions 
suggests that a properly formulated microneedle patch could enable influenza vaccine to 
be removed from the cold chain. Resistance to electron beam irradiation suggests that 
terminal sterilization may be possible, as opposed to the more costly scenario of aseptic 
manufacturing, which could enable significant cost savings.  
Influenza vaccine stability, however, requires proper formulation. It is well known 
that trehalose and sucrose are good lyoprotectants[172, 191, 194, 198, 199], and arginine, 
a basic amino acid, has been shown to both inhibit aggregation[119] and dry into an 
amorphous state[200]. Calcium heptagluconate has received limited attention as a 
stabilizer, but has been shown to stabilize hemoglobin in the liquid state,[201] which was 
the reason we included this excipient in our initial stabilizer screen. A possible reason for 
the success of multiple-stabilizer formulations relative to formulations using single 
stabilizers (i.e., in chips, without the presence of additional formulation excipients used in 
the complete microneedle patch production) is the inhibition of crystallization of one 
excipient by the other excipient(s).[202] 
Some microneedle patches were made without a stabilizer in the first mold fill. 
These patches showed significantly less active vaccine after fabrication, but did not have 
additional losses once dried and placed in storage. This indicates that the stabilizers 
included in the vaccine casting solution were needed predominately for stability during the 
fabrication process. Once the patches were completed, dried, and stored, the sucrose and 
PVA that compromise the bulk of the microneedles and backing provides sufficient 
stabilization to maintain vaccine activity during long-term storage. These findings of 
monovalent vaccine stability also held true for microneedle patches containing trivalent 
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influenza vaccine. A dose comparable to the full human dose in clinical use was 
incorporated into these patches, which suggests that these findings can be readily translated 
into microneedle patches used to administer seasonal influenza vaccine to people. 
As further tests of influenza vaccine stability in microneedle patches, patches 
utilizing the arginine/heptagluconate formulation were subjected to very high temperature, 
freeze-thaw cycling, and electron beam irradiation. Over a period of four months, vaccine 
in microneedle patches lost no significant activity when stored at 60°C. While we do not 
envision patches needing to withstand such a high temperatures for so long, it suggests that 
the microneedle patch could survive most any expected elevated thermal exposure that a 
seasonal influenza vaccine might experience during its one-year shelf life. The excellent 
stability during freeze-thaw cycling suggests the ability of influenza vaccine in 
microneedle patches to survive freezing that could occur due to handling errors or faulty 
cold-chain equipment. The ability of microneedle patches to preserve vaccine activity at 
both -80oC and after five consecutive freeze-thaw cycles could be associated with the 
relatively low moisture content of a few percent (data not shown). This small amount of 
water may be bound water that does not form ice crystals[203] or it may be phase-separated 
or otherwise in poor contact with the vaccine antigen, so that they do not interact.  
Of relevance to the anticipated future use of microneedle patches for clinical 
influenza vaccination, maintenance of vaccine activity after exposure to sterilizing 
irradiation by electron beam suggests that terminal sterilization of microneedle patches 
could be use. This would avoid the high cost of aseptic manufacturing and therefore 
represent a significant cost savings. These findings, however, should be tempered by the 
fact that there is evidence that damaging effects of electron beam irradiation may not be 
apparent until after storage[204] (which we did not study) and that the sterilization cycle 
used in this study is expected to be suitable for microneedle patch sterilization, but sterility 
of these patches was not verified.  
The primary test of vaccine activity in this work was performed by ELISA, which 
is a reasonable measure of vaccine stability, but is not the gold standard method, which is 
single radial immunodiffusion (SRID).[205] We did not use SRID in this study because it 
is a complex assay that is difficult to operate reproducibly and is relatively low throughput. 
Instead, we verified our in vitro findings with in vivo studies of immunogenicity in mice. 
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When compared to ID injection of a comparable vaccine dose, stored microneedle patches 
stored for more than one year at 25°C elicited an equal or stronger immune response after 
vaccination. This increase in antibody response when compared to ID delivery was seen in 
this study when using freshly made microneedles patch and has been noted before in the 
literature.[69, 197] To remove the effect of delivery route, stored microneedles were 
dissolved in water and injected ID. Mice receiving either fresh vaccine or stored vaccine 
delivered ID generated indistinguishable antibody responses, showing that the vaccine in 
the stored patches had retained its immunological activity. 
When considered in the context of the broader microneedle patch literature, we 
believe this study further suggests that influenza vaccination using microneedle patches 
could be a valuable improvement over current vaccination practice. Previous studies 
indicate that vaccination using microneedle patches provides improved immune responses, 
probably due to targeting of the vaccine to the skin.[206] In addition, microneedle patches 
are small, which facilitates storage, distribution and storage, and because they dissolve in 
the skin, microneedles generate no biohazardous sharps waste.[65, 70, 140, 171, 185, 186] 
In part because they are painless and can be self-administered, human subjects have 
indicated a strong preference for microneedle patches over hypodermic needle 
injections.[168] This study adds one more reason why influenza vaccination could benefit 
from microneedle patch administration; the remarkable thermostability demonstrated here 
suggests that influenza vaccine could be taken out of the cold chain to decrease costs, 
decrease vaccine spoilage and increase convenience of vaccination. 
 
5.5 Conclusion 
This study shows that influenza vaccine formulated into microneedle patches 
remained stable after storage for 18 months at 25°C, storage for four months at 60°C, 
exposure to five freeze-thaw cycles and irradiation during electron-beam sterilization. Most 
stability measurements were made by assessing activity of monovalent vaccine by ELISA; 
additional studies using trivalent influenza vaccine assessed by ELISA and measuring 
antibody responses in mice gave similar results. A microneedle patch for influenza 
vaccination with this high level of stability could enable vaccine storage and distribution 
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outside the cold chain to simplify and reduce costs of annual influenza vaccination 
campaigns and vaccine stockpiling for emergencies.   
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CHAPTER VI 
PROVIDE INSIGHTS INTO MECHANISMS OF INFLUENZA 
VACCINE ACTIVITY LOSS DURING DRYING  
 
6.1 Introduction 
It is estimated that up to 500,000 deaths occur each year worldwide due to influenza 
infections.[160] In addition to the human cost, there is also a large economic impact. In the 
United States alone, it is estimated the economy bears a burden between $70-167 billion 
each year.[207] The US Centers for Disease Control and Prevention recommend that 
everyone above the age of six months receive a seasonal influenza vaccination.[161] The 
current influenza vaccine is delivered primarily via hypodermic needle and syringe, 
although there is currently an alternative vaccine delivered intranasally.[208] Vaccine 
delivered by either of these routes must be stored and transported within the cold-
chain.[209] The ability to remove the cold-chain from consideration for a vaccine would 
lower vaccination campaign costs and lower the possibility of vaccine wastage or the 
delivery of non-immunogenic doses. 
A novel vaccine delivery system under development and currently undergoing 
clinical trials[210] is the microneedle patch. This technology utilizes an array of sub-
millimeter projections to deliver drugs directly into the skin.[59] Of particular interest to 
this work is the variety of microneedle patches that employs water soluble microneedles. 
These microneedles are composed of water-soluble excipients, such as sugars and 
polymers. The purpose of these excipients is to provide mechanical strength for insertion 
into skin, to enable quick dissolution after insertion, and to provide a stable environment 
for the drug, which is encapsulated inside of the microneedle itself.[176] This latter is of 
particular interest for the ability to remove these microneedle patches from the cold-chain. 
A common method of biopharmaceutical stabilization is lyophilization.[211] This 
process freezes a drug solution then removes the vast majority of water by sublimation and 
heating.[212] The removal of water, along with proper excipient selection, can help to 
stabilize the drug in a highly immobile state with fewer deleterious interactions.[189] Due 
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to the nature of microneedles as a solid dosage form, there is an opportunity for dry protein 
stabilization. This work is focused on elucidating the mechanism of influenza vaccine 
activity loss during drying as part of the microneedle manufacturing process and how 
certain formulations affect its stability. 
There are several different forms of influenza vaccine, but the most common form 
is the subunit vaccine. Subunit vaccines are composed primarily of membrane proteins of 
inactivated and broken down viral particles. In the case of the influenza vaccine, the 
principle antigenic protein of interest is hemagglutinin (HA).[131] HA is a ~225 kDa (i.e. 
3 x 75 kDa) homotrimer that is responsible for sialic acid binding on the surface of a target 
cell as well as membrane fusion to that cell, facilitating the introduction of viral cargo into 
the cell.[5] HA is synthesized as a single polypeptide precursor, HA0, which then non-
covalently associates into trimers. This non-active, fusion-incompetent assembly is cleaved 
during translation to the viral membrane to form a native, mature HA protein composed of 
two subunits, HA1 and HA2, linked by a single disulfide bond.[213] HA membrane fusion 
follows a conformational change to a fusogenic HA state brought on by low endosomal pH 
after endocytosis.[18] 
There has been previous work to stabilize influenza vaccine in various states such 
as liquid[214, 215], lyophilized[131, 216], spray (freeze)dried[20], and incorporated into 
microneedle patches[140]. This work, while generalizable to a degree, is focused on 
dissolvable microneedle patches where a vaccine/excipient solution is added to a 
microneedle patch mold and allowed to air dry. We have found that the changes to the HA 
protein upon drying are primarily related to tertiary structure changes as opposed to 
secondary structure changes, which can be predominately prevented with the choice of 
suitable formulation components. 
6.2 Methods  
6.2.1 Vaccine and reagents 
Monovalent vaccine stocks were generously provided by Novartis Vaccines and 
Diagnostics (Cambridge, MA). Influenza vaccines used were strains 
A/Christchurch/16/2010(H1N1), A/Texas/50/2012(H3N2), and 
A/Victoria/361/2011(H3N2). All three strains were used for circular dichroism and 
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intrinsic fluorescence experiments; A/Christchurch/16/2010(H1N1) and 
A/Texas/50/2012(H3N2) were used for dynamic light scattering and transmission electron 
microscopy experiments; A/Victoria/361/2011(H3N2) was used for proteolysis 
experiments. All excipients were purchased from Sigma-Aldrich (St. Louis, MO). Vaccine 
used in circular dichroism studies was buffer exchanged into 10 mM phosphate buffer with 
20 mM sodium fluoride (KPNF), pH 7.3, overnight at 4°C using ThermoFisher Slide-A-
Lyzer dialysis cassettes with a 10 kDa molecular weight cutoff (Waltham, MA). Vaccine 
used for all other studies was buffer exchanged twice at 6°C into 150 mM ammonium 
acetate, pH 7.0, with Sartorius (Göttingen, Germany) Vivaspin 500 centrifuge filters with 
a 30 kDa molecular weight cutoff. 
When dried vaccine samples were needed, the vaccine samples were dried for 24-
48 hours in Costar prelubricated microcentrifuge tubes at room temperature with desiccant 
and a vacuum of 85 kPa. When applicable, a solution of 30% excipient was mixed with the 
vaccine sample before drying. 
6.2.2 Dynamic light scattering (DLS) 
All DLS measurements were acquired on a Malvern Instruments Zetasizer Nano 
ZS90 (Malvern, UK) in Eppendorf UVette cuvettes (Hamburg, Germany). Data was 
acquired with ten 30 second measurements per sample. Data shown represent three samples 
per condition which were averaged with Malvern Zetasizer Software v7.11. 
6.2.3 Transmission electron microscopy (TEM) 
5 µl of influenza vaccine in suspension was placed onto 400 mesh carbon-coated 
copper grids that had been made hydrophilic by glow discharge. After 2 minutes, grids 
with the protein suspension were rinsed by briefly touching the sample side with three 
drops of distilled water. The residual water on the grids was then removed by wicking the 
edge of the grids with a piece of filter paper. For negative staining, 5 µl of 1% aqueous 
uranyl acetate was applied onto the grids immediately after water removal, and then wicked 
dry as described above after 10 seconds. Grids were left to completely dry prior to imaging 




6.2.4 Proteolysis digestion 
After reconstitution of dried vaccine and preparation of liquid vaccine samples, 1 
mg/mL proteinase K was added at a 1:1 v/v ratio of HA to proteinase K. This mixture was 
allowed to incubate at 25°C for one hour. After incubation with enzyme, 100% 
trichloroacetic acid was added at a 1:4 volume ratio. This mixture was incubated at 4°C 
followed by centrifugation to pellet the protein in each tube. This pellet was then rinsed at 
least three times with acetone. After allowing the residual acetone to dry, pellets were 
rehydrated. Samples were incubated for 10 minutes at 90°C with sodium dodecyl sulfate 
sample buffer lacking a reducing agent before being separated by electrophoresis using 170 
V across a 12% acrylamide gel for up to one hour and stained with Coomassie Brilliant 
Blue.    
6.2.5 Circular dichroism (CD) 
Heated samples were diluted to their final volume with KPNF and placed in a 75°C 
water bath for three hours. Liquid samples were diluted to their final volume with KPNF 
and scanned without further processing. All CD measurements were acquired on a Jasco J-
815 CD spectrometer (Easton, MD). Liquid samples were placed in Jasco 1 mm path length 
Q-quartz cuvettes and scanned at wavelengths from 250 nm to 190 nm at a 200 nm/min 
and 10 accumulations per sample. Post-analysis consisted of smoothing by the Savitzky-
Golay method and a convolution width of 9, scaling each curve at 220 nm, and averaging 
the three samples for each condition. 
6.2.6 Intrinsic protein fluorescence 
Dried vaccine samples were dried for 24 hours in Corning round bottom black 
microwell plates (Corning Inc., Corning, NY) at room temperature with desiccant and a 
vacuum of 85 kPa. When applicable, a solution of 30% excipient was mixed with the 
vaccine sample before drying. Dried samples were then rehydrated so that the fluorescence 
emission spectra could be acquired. Samples were excited at 280 nm and the emission was 
measured from 300-400 nm on a BioTek Synergy MX (Winooski, VT). To mitigate the 
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effect of noise during scanning, spectrum peak determinations were calculated by fitting a 
third-order polynomial to the raw fluorescence intensity from 300-350 nm. 
6.2.7 Statistics 
All statistics were calculated using Excel 2013 software (Microsoft, Redmond, 
WA). All listed averages represent the arithmetic mean of the tested samples. Comparisons 
between individual samples were performed using an unpaired t-test with a significance 
cutoff of p < 0.05. 
 
6.3 Results 
6.3.1 Electron microscopy 
Samples of vaccine were examined with a transmission electron microscope (TEM) 
to help clarify the results of DLS studies. TEM images showed an abundance of multimeric 
rosettes of HA molecules with a characteristic size of 30 – 40 nm, as is typical of subunit 
influenza vaccine[217] (Fig 6.1a). In addition, larger structures were also noted (Fig 6.1b). 
They appeared to be vesicle-like assemblies of HA molecules. They were typically in the 
size range of 100-200 nm in diameter, and the frequency of occurrence did not appear to 
be a function of sample preparation. 
 
Figure 6.1. Transmission light microscopy images of A/Texas/50/2012 at two 
magnifications to show (A) multimeric rosettes and (B) multimeric rosettes alongside 
larger protein assemblies. 
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6.3.2 Dynamic light scattering 
The distribution of hydrodynamic radii of vaccine components was determined 
using dynamic light scattering (DLS). Typical intensity distribution curves of liquid control 
vaccine reveal two unique peaks, the first at 20-40 nm diameter, which is interpreted as 
hemagglutinin (HA) rosettes[218], and the second at 100-300 nm diameter, which is 
interpreted as larger assemblies of HA (Fig 6.2a). The number distribution curve (Fig 6.2b) 
is dominated by the rosette population since a given intensity must consist of many more 
small particles compared to few large particles. When vaccine was dried (without addition 
of an excipient), reconstituted, and then examined by DLS, intensity size distributions 
shifted towards larger diameters while number size distributions had much less regularity. 
The addition of trehalose with the vaccine before drying maintained both an intensity size 
distribution and number size distribution similar to liquid control vaccine. 
 
Figure 6.2. Dynamic light scattering of A/Texas/50/2012 vaccine. Representative 
graphs showing (A) intensity size distribution and (B) number size distribution both 
show a size increase of dried vaccine but the retention of the original distribution 
when trehalose as excipient is added to the vaccine. Each curve represents an average 
distribution (n=3), as computed by the manufacturer’s software 
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6.3.3 Proteolysis assay 
To probe whether HA undergoes a natural conformational change during drying, 
HA molecules were exposed to potential proteolysis by proteinase K.[18] Shown in Figure 
6.3, unadulterated vaccine was not susceptible to enzyme digestion, as evident by the 
presence of the original full-length HA band (Lane C). Vaccine that had been heated, 
though, was not apparent on the gel after enzyme exposure, showing the ability of 
proteinase K to digest heat-treated vaccine (Lane D). Vaccine dried without an additional 
excipient was present on the protein gel (i.e., was not digested), leading to the interpretation 
that dried influenza vaccine does not undergo a conformational change. Several excipients 
were also included in the vaccine formulation before drying, showing no enzyme digestion 
when dried with trehalose or xylitol, yet xylose led to enzyme digestion after drying. 
 
Figure 6.3. SDS-PAGE of A/Victoria/361/2011 vaccine after exposure to proteinase K 
enzyme digestion. The white box represents the location of undigested HA. The 
absence of a band within that area is indicative that HA underwent proteolysis due to 
a conformational change prior to proteinase K incubation. (A) Vaccine only and (B) 
enzyme only are shown for reference, while (C) native vaccine and (D) heated vaccine 
were incubated with proteinase K as negative and positive controls. Vaccine was also 
dried with (E) no added excipient, (F) trehalose, (G) xylose, and (H) xylitol. Numbers 
on the left side indicate the molecular weight in kDa of reference proteins run 
concurrently. 
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6.3.4 Circular dichroism 
Evidence of secondary structure changes was probed with far-UV circular 
dichroism (CD) spectroscopy. Samples of three vaccine strains that had been dried, heated, 
or left as a liquid control were all examined with CD. CD data for no conditions were 
significantly different for A/Christchurch/16/2010(H1N1) and A/Texas/50/2012(H3N2) 
(Fig. 6.4a-b). Although the CD signal for A/Victoria/361/2011(H3N2) was nearly identical 
among the three conditions, the absorbance at 208 nm was significantly higher (Fig. 6.4c, 
Student’s t-test, p= 0.03) for vaccine which had been dried without trehalose. This value 
indicates that there may be a slight perturbation to the protein secondary structure. 
6.3.5 Intrinsic fluorescence 
Further study of possible secondary structure changes was undertaken with the use 
of intrinsic protein fluorescence. λmax values for refrigerated liquid control vaccine was 
compared to vaccine of the same strain that was dried with either trehalose or no added 
excipient or that had been heated in the liquid state. All experimental conditions yielded 
λmax values that were statistically different than that of the liquid control (Fig 6.5, Student’s 
t-test, p < 0.05), yet no differences were greater than 1.75 nm, which may represent a 
structure change slight enough to not have an effect on vaccine activity. All three strains 
showed an increase in λmax values, indicating a slight opening of tertiary structure and 
generally more solvent exposure of aromatic amino acids. Vaccine dried without an added 
excipient showed decrease in λmax values for A/Victoria/361/2011(H3N2) and 
A/Texas/50/2012(H3N2) but an increase in λmax values for 
A/Christchurch/16/2010(H1N1). This discrepancy can be attributed to either varying 
locations of aromatic residues amongst the strains or varying behavior upon drying. 
Finally, all three vaccine strains, when dried with trehalose included in the formulation, 
showed a slight, less than 1 nm, decrease in λmax values. These values were seen to be the 
same as liquid vaccine with trehalose added, thus attributing the decrease in λmax values to 
a change in solvent nature. Fluorescence spectroscopy was not able to definitively rule out 





Figure 6.4. Far-UV circular dichroism spectra of (A) A/Christchurch/16/2010, (B) 
A/Texas/50/2012, and (C) A/Victoria/361/2011. Experimental conditions shown 
include liquid control (solid line), dried overnight at room temperature (short dashed 
line), and heated for three hours at 75°C (long dashed line). Spectra were acquired at 




Figure 6.5. Wavelengths of peak intrinsic fluorescence for A/Victoria/361/2011 (n=3), 
A/Christchurch/16/2010 (n=9), and A/Texas/50/2012 (n=9) and at various 




Vaccine stability must be maintained for it to be efficacious once delivered 
regardless of its type or state. In the case of dissolving MN patches, that involves stability 
during drying. The work shown here was aimed at understanding more about how subunit 
influenza vaccine loses activity during air drying. Air drying is how dissolving MN patches 
for this work were produced and is therefore relevant but also may be distinct from other 
drying methods such as lyophilization or spray drying. 
Commercial subunit influenza vaccine was utilized as it is a vaccine currently being 
developed for human clinical trials. This vaccine has been seen to lose roughly half of its 
activity after drying at room temperature for 24 hours, though without the presence of a 
protecting excipient. The two general hypotheses studied here was that there could be 
structural changes, either secondary or tertiary, or that there could be irreversible 
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aggregation occurring. A variety of techniques were utilized to monitor for these changes. 
When applicable, a well-known stabilizer, trehalose, was added to the vaccine formulation 
to determine its effect on vaccine activity retention and its interference with whichever 
degradation pathways were found to be influential. 
When TEM was used to image vaccine samples, there were numerous rosettes of 
approximately 30-40 nm diameter, but also present were large spherical structures in the 
100-300 nm diameter range seen in DLS scans. It appears that there were HA molecules 
protruding from their surfaces. We hypothesize that these structures are reformed after HA 
molecules are separated from intact virions and can be thought of as analogous to micelle 
formation in surfactant solutions. Although a limitation of standard TEM analysis is the 
necessity of drying samples on mesh grids, there was no observable difference in the size 
or frequency of large HA structures amongst vaccine samples that had remained liquid 
until processing for TEM or samples that had been dried with or without trehalose. Also 
noted visually were unstructured agglomerations of protein which did not appear correlated 
with drying condition. This was performed by visual analysis of a set of TEM images; 
further study with a higher resolution TEM instrument and image analysis may yield more 
conclusions. When vaccine samples were examined with DLS, there was clearly a 
population consisting of multimeric rosettes, which is typical of subunit influenza vaccine. 
These rosettes are formed because of the interaction of multiple HA molecules’ 
hydrophobic transmembrane regions.[219] Alongside the rosette population, there was also 
a larger population (i.e., 30 – 40 nm) that was rather large to be intact virions (i.e., ~80 – 
100  nm[220]) that were not broken apart during vaccine production. 
Although there was no visual difference between vaccine conditions examined with 
TEM, there was a marked difference between liquid vaccine and dried vaccine measured 
by DLS. While liquid control vaccine displayed two consistent, distinct peaks, vaccine 
which had been dried without excipients and reconstituted gave a signal which was not as 
smooth and was relatively variable for multiple samples. It is unclear what form the new 
species were, but the lack of or shift of the rosette peak was apparent in drying conditions 
associated with a loss of vaccine activity seen previously. Vaccine dried with trehalose, on 
the other hand, displayed the same two DLS peaks as liquid vaccine. This can be attributed 
to trehalose’s ability to form a glass phase during drying that is extremely viscous and 
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immobilizes entities contained inside it.[89] Saccharides are also known as kosmotropic 
agents.[221-223] Kosmotropic agents, in general, strongly interact with water and are 
excluded from the solvation layer of proteins.[224] This leads to a decrease in water 
diffusion around the surface of the protein, lowering the flexibility and stabilizing the 
protein.[225] The kosmotropic nature of trehalose likely decreases protein-protein 
interaction causing an impediment to aggregation. Further analysis of vaccine particle sizes 
distributions and species could be carried out with a gel filtration experiments. If these 
species could be separated, then the activity of various species could be tested. 
This kosmotropic behavior was also evident when vaccine was probed for intrinsic 
fluorescence. Overall, there was little, but statistically significant, difference in peak 
intensity wavelength, λmax, amongst the experimental conditions tested. Vaccine dried with 
trehalose showed a blue-shift of λmax indicating a less exposed environment of the HA 
protein’s aromatic residues.[156] Control samples of liquid vaccine with added trehalose 
also showed similar drops in λmax, suggesting that the change seen in vaccine dried with 
trehalose is caused by the presence of trehalose in solution after rehydration. As for vaccine 
dried without an excipient, results were more varied. λmax increased for one strain and 
decreased for the other two. Notably, the two strains that behaved similarly were 
A/Victoria/361/2011 and A/Texas/50/2012, which have a 98.6% sequence identity, so the 
corresponding results are not surprising. The differing fluorescence behavior could be 
attributed to different numbers of tyrosine and tryptophan between the H1N1 and H3N2 
strains. Finally, heated samples showed a consistent red-shift of λmax consistent with a 
general loosening of tertiary structure and exposure of aromatic residues.[156] 
Additional inspection of secondary structure was undertaken with CD 
spectroscopy. Similarly to intrinsic fluorescence spectroscopy, there were little to no 
differences found between experimental groups. It is well known that HA undergoes a 
conformational change at low endosomal pH or elevated temperatures.[226] It was 
expected that heated vaccine would show a change in CD spectrum compared to control 
vaccine, yet this was not seen. Vaccine availability limited this work to far-UV CD, but 
given a large enough vaccine stock for concentrated samples, near-UV CD may be able to 
detect more subtle changes to protein structure. When vaccine was dried, there were no 
spectrum changes for A/Texas/50/2012 and A/Christchurch/16/2010(H1N1), but there was 
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a slight change in A/Victoria/361/2011 when dried, indicative of a loss of α-helical 
nature.[227] It is unclear with the techniques utilized to pinpoint the exact location of this 
structure change, whether it is in a region containing antibody-generating epitopes 
Besides the two spectroscopic methods already discussed, the fusion-based 
conformational change of HA can be monitored by enzyme proteolysis.[16] Native-
conformation HA is resistant while HA in the fusogenic state is susceptible to cleavage of 
the HA1 polypeptide near its disulfide connection to HA2.[18] As expected, non-heated 
and heated vaccine samples were resistant and susceptible to cleavage, respectively. The 
test condition of dry vaccine was shown to be resistant to proteolytic cleavage. The stresses 
of drying does not affect HA in a way that would cause a conformational change detected 
by this assay. Therefore, the stabilizing effects of trehalose were not needed, and trehalose 
addition did not have an effect on HA cleavage. Besides trehalose, we chose to test vaccine 
drying with xylitol and xylose as well, since they performed very well and very poorly, 
respectively, during early formulation screening experiments.[195] The reason for vaccine 
activity loss during drying in the presence of xylose is apparently associated with the 
induction of a conformational change. Xylose is a reducing sugar, which implicates a likely 
reaction with the side chain of an amino acid residue. Influenza vaccine cannot be stabilized 
by the inclusion of any saccharide, or even any non-reducing saccharide. For example, 
lactose, a reducing sugar, was a successful stabilizer, suggesting that there are other factors 
involved in the ability of a sugar to stabilize HA during drying. 
With this insight into the mechanisms of influenza vaccine activity loss, we hope 
that formulation knowledge can be applied for various vaccines. Excipient properties 
appearing to contribute to the ability of an excipient to stabilize influenza vaccine are a 
kosmotropic nature and the ability to form a glass phase to prevent aggregation. As these 
do not depend directly on the specific protein, other subunit vaccines could possibly work 
well in similar formulations. A limitation of this work includes the lack of information 
regarding whether there were any specific interactions between trehalose and the protein 
during drying. Specific interactions could make the application of top stabilizing 
formulations less generalizable to multiple vaccines or even strains of the same vaccine, as 
the amino acid sequence of influenza vaccines can change from year to year. Another 
limitation is the unknown nature of the aggregation pathways during drying of vaccine 
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without a stabilizer. These aggregates could change over time without an excipient or could 
also be affected by possible changes to the excipient environment over time during 
storage.[172] The protein secondary and tertiary structure remained unchanged in most 
cases during drying. This consistent structure would benefit the production of antibodies 




Vaccine stability is vitally important to immunization campaigns due to both the 
large percentage of overall cost the cold-chain represents as well as vaccine wastage and 
non-efficacious doses due to faults in the cold-chain during storage and transportation. 
Microneedle patches represent a promising vaccine delivery method with numerous 
advantages over current vaccination methods, but the drying of vaccines during production 
and storage poses a barrier to commercialization. This work, which focused on subunit 
influenza vaccine, aimed to determine the mechanism(s) of vaccine activity loss during air 
drying. The predominant change to vaccine structure was aggregation as opposed to 
significant secondary or tertiary structure changes to the influenza hemagglutinin protein. 
Formulations that prevent hemagglutinin aggregation are expected to stabilize influenza 
vaccine doses in a dried state and possibly allow for their removal from the cold-chain. Our 
hope is that this work will further the development of microneedle patches for influenza 
vaccine as well as other vaccines which could benefit from the advantages of microneedle 
patch technology.  
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A novel drug delivery system under development is the dissolving microneedle 
patch. When compared to the standard hypodermic needle and syringe currently used for 
most immunizations, MN patches provide numerous benefits. From the patient’s 
perspective, MN patches are a painless alternative to a hypodermic injection. There is also 
the possibility that patients will be able to self-administer vaccinations without the 
assistance or observation of a healthcare worker. The ability to pick up a vaccine MN patch 
at a pharmacy or grocery store for oneself and one’s family to be used painlessly at home 
is likely to raise a population’s acceptance to receiving a vaccine and increase vaccination 
coverage. While there will be biohazardous waste, it is not sharps waste, thus simplifying 
waste disposal. Also, there is evidence that immunization by MN patch is more 
immunogenic than an intramuscular injection.[69] This opens two possibilities. Either 
delivery of the same dose as an intramuscular injection generates an improved immune 
response, or the dose of vaccine delivery can be lowered, thus saving cost and spreading 
the current vaccine production over more doses. 
A key to simplifying vaccination logistics is the capability of MN patches to be 
stored and transported outside of a controlled cold-chain. Most commercial vaccines must 
remain refrigerated or frozen until immediately before delivery. This can be cumbersome 
and very expensive, especially in developing countries, where the cold-chain is much less 
reliable.[228] Even in developed countries, cold-chain storage adds a significant cost to 
any vaccine program. Vaccine outside of the cold-chain by faulty or unavailable equipment 
as well as by human error is typically discarded. This vaccine waste is an expensive, but 
avoidable cost for vaccine programs. 
MN patches are able to maintain vaccine activity outside of the cold-chain by means 
of keeping the vaccine in a dried state, where degradation pathways can be significantly 
slowed or eliminated. The primary method of modulating vaccine stability is through MN 
patch formulation development. Excipients added to the solutions used in the patch 
production process can have a positive or negative effect on vaccine stability. They also 
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must be safe for use in humans and retain the patch’s ability to insert into skin and dissolve 
within a reasonable time. 
Working towards a thermostable influenza dissolving MN patch, this work began 
with a screen of factors possibly affecting influenza vaccine stability during drying, 
followed by the implementation of several leading candidate formulations in the production 
of MN patches which were stressed by various means, stored at room temperature for 
extended periods, and used to vaccinate mice as a verification of in vivo immunogenicity. 
Formulation screening was performed on flat polydimethylsiloxane (PDMS) and 
stainless steel (SS) surfaces referred to as “chips”. These chips represented the surface 
vaccine is dried on when making dissolving and coated MN, respectively. The use of chips 
greatly increased the throughput of screening compared to full MN patches, as well as 
allowed for isolation of particular variables, since MN patch production is a more intricate 
process. The rate of initial drying, from ten minutes to one hour, as dictated by drying 
temperature, did not have a significant impact in most cases so room temperature drying 
was chosen to avoid complicating patch production. Concurrently, buffer salts were tested. 
Phosphate buffered saline, which is what commercial influenza vaccine is delivered in, did 
not perform well, likely owing to a drop in pH during drying. This is commonly seeing 
during freezing of protein solutions,[83]thus this buffer should be avoided. With both (4-
(2-hydroxyethyl)-1-piperazineethanesulfonic acid) (HEPES) and ammonium acetate being 
successful at maintaining vaccine activity, a choice of buffer needed to be made. 
Ammonium acetate was chosen as the buffer for all future stability studies in part because 
of its stabilizing capability but also because it is a volatile salt, where its constituent ions, 
acetate and ammonium, form two volatile compounds, acetic acid and ammonia, 
respectively. The hypothesis is that the presence of salts in the final matrix may lead to 
unfavorable interactions, thus ammonium acetate was chosen to prevent a possibly 
damaging scenario. 
A relatively large screen of excipient compounds contained a range of good 
stabilizers and bad stabilizers. Unsurprisingly, carbohydrates dominated the top list of good 
stabilizers. It’s well known that carbohydrates have stabilizing properties for proteins in a 
dry state.[191] Many of them form an amorphous glassy phase when dried that has such 
high viscosity that anything in the solution initially is subsequently confined and 
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immobilized. Degradation pathways that involve protein mobility are therefore impeded. 
Many carbohydrates also are capable of interacting favorably with proteins via their 
numerous carboxyl groups.[192] 
Previous work in our lab has shown that certain stabilizing compounds, such as 
trehalose and sucrose, tend to crystallize over time, which is unfavorable for protein 
stability.[172] Also in our lab and in the literature[189], combinations of stabilizers have 
performed better over time than either of the constituent stabilizers did by themselves. Here 
stabilizer combinations were screened, and it was found that even stabilizers that performed 
well during initial vaccine drying lost activity over time, whereas certain combinations of 
those stabilizers fully maintained vaccine activity. These top stabilizer combinations were 
trehalose/sucrose, sucrose/arginine, and arginine/heptagluconate. The likely cause of the 
combinations’ success is the inhibition of crystallization by the presence of “impurities”, 
the other excipients.[229] 
Once the large number of possible formulations had been narrowed down, the top 
formulations were utilized to produce monovalent and trivalent influenza vaccine 
dissolving MN patches. The formulations were largely successful in this regard as well. 
High stability over a period of eighteen months at room temperature was observed, which 
is very promising for feasibility of storage of commercial MN patches outside of the cold-
chain. Since influenza is typically manufactured as a seasonal, annual vaccine, eighteen 
months of stability exceeds the necessary shelf-life. In the case of a pandemic vaccine to 
be stockpiled, though, a longer shelf-life may be necessary. The patches with 
arginine/heptagluconate as stabilizers generally performed the best, but all patches retained 
most of their activity. Even patches produced with a vaccine solution lacking a stabilizer 
retained vaccine activity during storage after an initial loss during production. This leads 
to the hypothesis that the primary mode of action of stabilizing excipients is to protect the 
vaccine payload from the stresses of drying during production. After the patches are 
complete, the sucrose and polyvinyl alcohol making up the bulk of the MNs and backing 
are sufficient to preserve vaccine activity during storage. 
The robustness of the influenza vaccine MN patches developed here has several 
ramifications. The resistance to vaccine and patch degradation during irradiation by 
electron beam opens up possibilities for terminal sterilization. This would allow for a 
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simpler and cheaper commercial production process compared to an aseptic production. 
Also, the patches’ ability to withstand both freeze-thaw stresses and elevated temperatures 
for extended periods lessens the concern that MN patches may deliver a suboptimal dose 
of vaccine after extensive storage and transportation. 
There was already evidence that vaccination via MN patch could be more 
immunogenic compared to an identical dose delivery via intramuscular or intradermal. In 
our immunogenicity study with fresh and aged patches, patches elicited higher antibody 
titers than an equivalent dose delivered intradermally. Again, this would permit for either 
a stronger immune response with a standard influenza vaccine dose or the ability to deliver 
less vaccine to generate a sufficient response, allowing the current manufacturing quantity 
to be used to vaccinate more people. 
Finally, we took a closer look at the mechanism of influenza vaccine activity loss. 
Further knowledge of the mechanism could aid in the development of MN patches for other 
vaccines, specifically those of the subunit variety. It was found that the primary mode of 
activity loss was the aggregation of viral proteins, preventing antibody recognition of those 
proteins and likely also preventing an immune response in the form of antibody generation. 
Investigation by circular dichroism, intrinsic fluorescence, and enzyme digestion showed 
little if any change to the immunogenic protein, hemagglutinin, during drying, even without 
a stabilizer included in the formulation. There were, however, changes in the hydrodynamic 
size distribution, as seen with dynamic light scattering. Addition of trehalose in dried 
samples led to a size distribution comparable to liquid samples, typically at full or near-full 







8.1 Extension of successful formulations to other vaccines 
This work was performed solely with influenza subunit vaccine. While stability of 
this vaccine in microneedle patches outside of the cold-chain was achieved, there are a 
myriad of vaccine types for different diseases. The ability to incorporate more vaccines 
into microneedle patches will benefit the fight against vaccine preventable illnesses and 
deaths as well as to help further the reach of this delivery method. Influenza subunit vaccine 
is composed primarily of hemagglutinin and neuraminidase proteins. While these are 
membrane proteins, the stabilizing properties of the stabilizing formulations developed in 
this work should translate well to the stabilization of other proteins, whether part of a 
vaccine or other therapeutic. The glassy phase trehalose likely forms during air drying is  
thought to prevent irreversible aggregation of proteins upon drying is relatively 
independent of the drug payload assuming the loading drug is of relatively low weight 
percent of overall solids content. 
The ability of the formulations developed in this work to protect other types of 
vaccines is less certain. For example, whole inactivated vaccines, such as influenza and a 
variety of polio vaccine, are intact virions, whose size retention is sensitive to external 
effects such as osmotic pressure.[230] It is possible that trehalose would help protect the 
proteins involved but may not be capable of maintaining all conditions needed for full 
vaccine activity. The antigens for influenza and polio vaccines are a membrane bound 
protein and an exterior protein capsid[220], respectively, so the capacity for certain 
formulations to stabilize different structures must be verified. In addition to protein 
structural changes, osmotic pressure and spatial confinement can greatly damage larger 
viral structures.[122] A step further in stabilization difficulty would be live attenuated 
vaccines such as measles, where the viral particles must retain the ability to replicate within 
the recipient to generate an appropriate immune response. Therefore not only must the 
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overall structure persist intact, but the interior machinery needs to be preserved enough for 
replication to proceed after delivery. Vaccines consisting of nucleic acids such as DNA 
plasmids bring a whole new set of parameters to stability. DNA supercoiling is strongly 
correlated to activity and stability.[231] These vaccine would require separate study. 
8.2 Inclusion of adjuvants in microneedle formulations 
Adjuvants are substances which are modulates or increases the immune response 
to a given antigen. Vaccine delivery into the skin can give an increased immune response 
compared to intramuscular injection, and adjuvant will likely only increase a vaccine’s 
potency. The two most popular vaccine adjuvants currently in human use are aluminum 
salts and squalene. The exact mechanisms of adjuvant action are still under investigation, 
but their inclusion in vaccine dosages can allow for dose sparing or more effective 
vaccines. Thus they are of great interest for inclusion into microneedle patch designs. Any 
excipient included in a microneedle patch formulation could possibly effect the outcome 
of the drug delivery. Aluminum salts, if included at a significant weight percent could 
affect the integrity of the microneedles or the ability of the other excipients to stabilize the 
vaccine to be delivered. The microneedles can also become rubber or brittle, preventing 
insertion into the skin. 
Squalene is not an adjuvant in its own right, but is combined with surfactants to 
produce and oil-in-water emulsification. It is unlikely that including an emulsification in 
the vaccine formulation will allow for the creation of microneedles, but it is worth 
investigating whether the components, such as squalene, Tween 80, and Span 85 found in 
the adjuvant MF59 by Novartis, can be incorporated into microneedles and delivered 
concurrently with a vaccine.  
There are other compounds being studied as potential adjuvants for human 
vaccines. These include cytokines, carbohydrates, and bacterial peptidoglycans. If these 
progress through further development, they would be promising adjuvants to include in the 
production of microneedle patches for vaccine delivery. Cytokines are small proteins 
which would likely be stabilized similar to viral antigens proteins. Carbohydrates are 
already commonplace in dry biopharmaceutical preparations, and peptidoglycans are 
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polymers of sugars and amino acids. Both carbohydrates and peptidoglycans would likely 
assimilate well into microneedle formulations.  
 
8.3 Rapid dissolution of microneedles 
There have been several studies investigating the feasibility of vaccine delivery via 
dissolving microneedle patches. A noted concern from patch recipient is the long wear time 
needed to allow for microneedle dissolution and delivery of the vaccine.[232] Decreasing 
the time required for complete delivery will both ease the administration procedure and 
increase the recipient’s acceptability. 
A possible method of decreasing the wear time is to include a superdisintegrant into 
the formulation.[233] One mechanism of action is to promote the penetration of moisture 
into the microneedle through wicking, breaking it into small pieces and creating more 
surface area to allow more moisture penetration. Another mechanism is to swell when in 
contact with water, overcoming the adhesiveness of other compounds present. Common 
superdisintegrants are crosslinked versions of cellulose, starch, or polyvinylpyrrolidone. 
They would be added to a small degree in either the initial vaccine fill and/or the polymer 
backing solution. 
Another method of decreasing the wear time would be to add another fill step to 
the production process. This step would add a layer between the layer at the tip of the 
microneedle containing the vaccine payload and the polymer backing. The added layer 
would contain compounds such as superdisintegrants or salts that dissolve nearly 
immediately upon insertion into the skin. The dissolution of this layer will separate 
microneedle from the back, leaving the microneedle to dissolve at an arbitrary rate inside 







The development of vaccines within the last century has helped bring an era of 
extended lifespans and less suffering from what are now known as vaccine-preventable 
diseases. There will undoubtedly be more diseases to earn that label, but there is still work 
to be done with currently proven and approved vaccines. Microneedle patches are a very 
promising novel drug delivery system that can be utilized to improve vaccinations. In 
addition to the benefits including absence of biohazardous sharps waste, painless self-
administration, and increased immunogenicity, MN patches could allow for the storage and 
transportation of vaccine doses outside of the cold-chain. Through systematic screening of 
MN patch formulations, we have developed a MN patch that maintained influenza vaccine 
activity when stored for up to a year and a half at room temperature. In addition, these 
patches were shown to be robust in ways that would benefit production and their resistance 
to storage errors. Through in-depth analysis of vaccine inactivation during drying, the 
formulations developed here may likely assist in the advancement of MN patch technology 
for the delivery of other vaccines besides influenza vaccine. The impact of the work 
described here can best be characterized by its applicability to a range of systems. 
Lyophilized protein stability is still a relatively empirical field where novel formulations 
are welcome. The development of microneedle systems is much newer than lyophilization, 
and the stability and formulation considerations are much less well-known for this novel 
drug delivery method. Formulations which both maintain vaccine activity and form proper 
microneedle patches are still under development. This work describes such formulations 
and gives more support to the eventual commercialization and implementation of 
microneedle to solve healthcare problems. Much work is remains to be done to rid 
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